Track market-moving stories before they get noisy

Now with a new route of induction administration, subcutaneous SKYRIZI supports early symptomatic and endoscopic control with an on-body injector (OBI) device throughout the course of treatment In the pivotal Phase 3 AFFIRM study, subcutaneous (SC) SKYRIZI® achieved superior clinical remissioni and endoscopic responseii at week 12 compared with placebo in patients with Crohn's disease; results were particularly strong in patients without prior advanced therapy failureiii The safety profile of subcutaneous induction was generally consistent with the established SKYRIZI profile in Crohn's disease, with no new safety risks identified FDA also approved an update to the U.S. Prescribing Information warning and precautions across all indications to allow healthcare providers to use clinical judgment when determining whether tuberculosis (TB) testing is needed , /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced the U.S. Food and Drug Administration has approved a subcutaneous (SC) induction regimen for SKYRIZI® (risankizumab-rzaa) for adults with moderately to severely active Crohn's disease (CD)iv. Patients now have the option to start SKYRIZI treatment at home, with induction doses delivered by an on-body injector (OBI) induction pack and then continue using an OBI once every eight weeks throughout the course of maintenance treatment.

"People living with Crohn's disease need treatments that can deliver meaningful disease control from the start," said Roopal Thakkar, M.D., executive vice president, research and development, chief scientific officer, AbbVie. "With the approval of subcutaneous induction, we are building on the strong efficacy of SKYRIZI while giving patients and physicians greater flexibility in how treatment is initiated. This is one more example of how AbbVie continues to advance treatment to better meet the needs of people living with Crohn's disease."

Subcutaneous SKYRIZI Shows High Rates of Clinical Remission and Endoscopic Response by Week 12iii 
This FDA approval is supported by positive results from the Phase 3 AFFIRM trial evaluating the efficacy and safety of SC SKYRIZI versus placebo in patients with moderately to severely active CD.iii SKYRIZI achieved superiority of the co-primary endpoints of clinical remission and endoscopic response at week 12.iii Although the study enrolled a primarily treatment-refractory population, these Phase 3 results were particularly strong within patients without prior advanced therapy failure (advanced therapy-naïve).iii By week 12, nearly three-quarters (74%) of advanced therapy (AT)-naïve patients were in clinical remission (vs. 27% placebo) and these AT-naïve patients achieved endoscopic response at four times the rate of placebo (60% vs. 15%, respectively).iii SC SKYRIZI also had a higher efficacy response in patients who had previously failed advanced therapy.iii

SC SKYRIZI also met secondary endpoints including endoscopic remission and FACIT fatigue scores at week 12 vs. placebo.iii The safety profile of SC SKYRIZI for induction was generally consistent with its known profile in CD, with no new safety risks observed.iii

Together, these results demonstrate market-leading clinical and endoscopic outcomes in advanced therapy-naïve patients that set a high bar in CD. Furthermore, the strength of these subcutaneous results provides a compelling foundation for future clinical trials.

AFFIRM Phase 3 Proportion of Patients Meeting Efficacy Endpoints at Week 12iii

Total Population

Prior Advanced Therapy
Failurea

Without Prior Advanced
Therapy Failureb 
(Advanced Therapy-Naïve)

Proportion of
Patients

Placebo

N=94

Skyrizi SCc

N=180

Placebo

N=61

Skyrizi SCc

N=115

Placebo

N=33

Skyrizi SCc

N=65

Clinical
Remissiond,e

30 %

56 %h

31 %

45 %

27 %

74 %

Endoscopic
Responsed,f

15 %

43 %h

15 %

33 %

15 %

60 %

Endoscopic
Remissiong

11 %

26 %h

11 %

17 %

9 %

43 %

a. Prior advanced therapy failure includes inadequate response, loss of response, or intolerance to one or more biologic or Janus Kinase inhibitor (JAKi) treatments for CD

b. Without prior advanced therapy failure includes patients who were naïve to biologics or JAKi, or patients who had never failed or demonstrated intolerance to biologics or JAKi

c. SKYRIZI 720 mg as a subcutaneous injection at Week 0, Week 2, Week 4, and Week 8

d. Co-primary endpoints

e. Defined as Crohn's disease activity index (CDAI) < 150

f.  Defined as a decrease in Simplified Endoscopic Activity Score for Crohn's disease (SES-CD) > 50% from baseline, or a decrease of at least 2 points for subjects with a baseline
    score of 4 and isolated ileal disease, based on central reading

g. SES-CD ≤ 4 and at least a 2-point reduction from baseline, with no individual subscore greater than 1, based on central reading
h. p <0.001 compared to placebo in total population.

Subcutaneous Treatment With SKYRIZI Offers Fully Self-Administered Therapy From the Start 
The induction dosing regimen with SC SKYRIZI is 720 mg delivered by OBI induction pack at weeks 0, 2, 4 and 8.iii Patients also have the option to start treatment intravenously with 600 mg delivered at weeks 0, 4 and 8.iii Patients can then continue with maintenance dosing starting at week 12 administered by OBI every eight weeks.iii

"When patients and I discuss treatment, they want to know two things: will it work? And how will it fit into their lives?" said Millie D. Long, M.D., MPH, chief, division of gastroenterology and hepatology, University of North Carolina at Chapel Hill, and lead investigator of AFFIRM. "AFFIRM answered the first question, with superior rates of clinical remission and endoscopic response versus placebo during induction with subcutaneous SKYRIZI, particularly in patients new to advanced therapy. This approval answers the second. As a physician who has used the SKYRIZI OBI, I've seen firsthand the convenience it can offer patients. Now with this approval, patients can start treatment at home and continue the same way through maintenance."

Patients Report Satisfaction and Ease of Use in Real World Experience With SKYRIZI OBI
First introduced in 2022 for CD maintenance treatment, the SKYRIZI OBI has demonstrated strong user experience. In a real-world survey of 186 people living with CD, 88% reported AbbVie's OBI easy to use.v In evaluating alternative routes of administration, a patient-reported survey of 352 adults living with IBD found 87% were satisfied or highly satisfied with OBI compared to 71% with an autoinjectorvi, demonstrating patient preference for OBI.

FDA Also Approved Update to Tuberculosis (TB) Language in U.S. Prescribing Information
Additionally, the FDA approved an update to the SKYRIZI prescribing information's warning and precautions language across all approved indications.iii The revised label advises healthcare providers to consider TB evaluation prior to treatment initiation based on clinical judgment.iii This change gives healthcare providers greater flexibility in patient assessment before starting SKYRIZI treatment. There is no mandatory TB test prior to initiating SKYRIZI.

About Crohn's Disease 
Crohn's disease is a chronic, systemic disease that manifests as inflammation within the gastrointestinal tract, most commonly in the area between the small intestine (ileum) and the colon, causing persistent diarrhea and abdominal pain.vii,viii It is a progressive disease, meaning it gets worse over time and may lead to life-threatening complications or surgery.ix,x Because the signs and symptoms of Crohn's disease are unpredictable, it causes a significant burden on people living with the disease—not only physically but also emotionally and economically.xi

About the AFFIRM Studyxii
AFFIRM is a global, Phase 3, randomized, placebo-controlled, double-blind study to evaluate the efficacy and safety of risankizumab subcutaneous (SC) as an induction treatment in adult patients with moderately to severely active Crohn's disease. Co-primary endpoints were percentage of participants with CDAI Clinical Remission (CDAI < 150) and percentage of participants with endoscopic response at week 12. A total of 274 patients were randomized in a 2:1 ratio to risankizumab SC or placebo. Key demographics and baseline characteristics were generally balanced between the risankizumab SC and placebo groups; 65% had failed advanced therapies for the treatment of CD before. The study consists of three treatment periods: a placebo-controlled Period A (baseline to week 12) to evaluate the efficacy and safety of risankizumab SC induction treatment, an extended Period B (week 12 to 24) where patients receive blinded or open-label treatments based on their clinical response at week 12, and a 52-week open-label extension Period C where all patients receive the approved risankizumab maintenance treatment.xii More information on this trial can be found at www.clinicaltrials.gov (NCT06063967).xii

Patient Access and Support
AbbVie is committed to helping people access SKYRIZI and other medicines, including offering a patient support program and co-pay card that may reduce out-of-pocket costs to as little as $0 per month for eligible, commercially insured patients. For those with limited or no health insurance, AbbVie offers myAbbVie Assist, a patient assistance program that provides SKYRIZI at no charge to those who qualify. More information about this assistance program can be found at www.AbbVie.com/myAbbVieAssist.

About SKYRIZI® (risankizumab-rzaa)
SKYRIZI is an interleukin-23 (IL-23) inhibitor that blocks IL-23 by selectively binding to its p19 subunit. IL-23, a cytokine involved in inflammatory processes, is thought to be linked to a number of chronic immune-mediated diseases.iii SKYRIZI is approved by the U.S. Food and Drug Administration (FDA) for the treatment of moderately to severely active ulcerative colitis, plaque psoriasis, psoriatic arthritis and Crohn's disease.iii

SKYRIZI® (risankizumab-rzaa) U.S. Uses and Important Safety Informationiii
SKYRIZI is a prescription medicine used to treat:

moderate to severe plaque psoriasis in adults and children 6 years of age and older who may benefit from taking injections or pills (systemic therapy) or treatment using ultraviolet or UV light (phototherapy). active psoriatic arthritis in adults and children 6 years of age and older. moderately to severely active Crohn's disease in adults. moderately to severely active ulcerative colitis in adults. IMPORTANT SAFETY INFORMATION

What is the most important information I should know about SKYRIZI® (risankizumab-rzaa)?

SKYRIZI is a prescription medicine that may cause serious side effects, including:

Serious allergic reactions:

Stop using SKYRIZI and get emergency medical help right away if you get any of the following symptoms of a serious allergic reaction: fainting, dizziness, feeling lightheaded (low blood pressure) swelling of your face, eyelids, lips, mouth, tongue, or throat trouble breathing or throat tightness chest tightness skin rash, hives itching Infections:
SKYRIZI may lower the ability of your immune system to fight infections and may increase your risk of infections. Your healthcare provider may check you for infections and tuberculosis (TB) before starting treatment with SKYRIZI and may treat you for TB before you begin treatment with SKYRIZI if you have a history of TB or have active TB. Your healthcare provider should watch you closely for signs and symptoms of TB during and after treatment with SKYRIZI.

Tell your healthcare provider right away if you have an infection or have symptoms of an infection, including: fever, sweats, or chills cough shortness of breath blood in your mucus (phlegm) muscle aches warm, red, or painful skin or sores on your body different from your psoriasis weight loss diarrhea or stomach pain burning when you urinate or urinating more often than normal Do not use SKYRIZI if you are allergic to risankizumab-rzaa or any of the ingredients in SKYRIZI. See the Medication Guide or Consumer Brief Summary for a complete list of ingredients.

Before using SKYRIZI, tell your healthcare provider about all of your medical conditions, including if you:

have any of the conditions or symptoms listed in the section "What is the most important information I should know about SKYRIZI?" have an infection that does not go away or that keeps coming back. have TB or have been in close contact with someone with TB. have recently received or are scheduled to receive an immunization (vaccine). Medications that interact with the immune system may increase your risk of getting an infection after receiving live vaccines. You should avoid receiving live vaccines right before, during, or right after treatment with SKYRIZI. Tell your healthcare provider that you are taking SKYRIZI before receiving a vaccine. are pregnant or plan to become pregnant. It is not known if SKYRIZI can harm your unborn baby. are breastfeeding or plan to breastfeed. It is not known if SKYRIZI passes into your breast milk. become pregnant while taking SKYRIZI. You are encouraged to enroll in the Pregnancy Registry, which is used to collect information about the health of you and your baby. Talk to your healthcare provider or call 1-877-302-2161 or visit http://glowpregnancyregistry.com to enroll in this registry. Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

What are the possible side effects of SKYRIZI?

SKYRIZI may cause serious side effects. See "What is the most important information I should know about SKYRIZI?"

Liver problems may happen while being treated for Crohn's disease or ulcerative colitis: A person with Crohn's disease who received SKYRIZI through a vein in the arm developed changes in liver blood tests with a rash that led to hospitalization. Your healthcare provider will do blood tests to check your liver before, during, and at least up to 12 weeks of treatment, and may stop treatment with SKYRIZI if you develop liver problems. Tell your healthcare provider right away if you notice any of the following symptoms: unexplained rash, nausea, vomiting, stomach (abdominal) pain, tiredness (fatigue), loss of appetite, yellowing of the skin and eyes (jaundice), and dark urine.

The most common side effects of SKYRIZI in people treated for Crohn's disease and ulcerative colitis include: upper respiratory infections, headache, joint pain, stomach (abdominal) pain, injection site reactions, low red blood cells (anemia), fever, back pain, urinary tract infection, and rash.

The most common side effects of SKYRIZI in people treated for plaque psoriasis and psoriatic arthritis include: upper respiratory infections, headache, feeling tired, injection site reactions, and fungal skin infections.

These are not all the possible side effects of SKYRIZI. Call your doctor for medical advice about side effects.

Use SKYRIZI exactly as your healthcare provider tells you to use it.

SKYRIZI (risankizumab-rzaa) is available in a 150 mg/mL prefilled syringe and pen, a 55 mg/0.37 mL prefilled syringe, a 600 mg/10 mL vial for intravenous infusion, and a 180 mg/1.2 mL or 360 mg/2.4 mL single-dose prefilled cartridge with on-body injector.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

If you are having difficulty paying for your medicine, AbbVie may be able to help.

Visit AbbVie.com/PatientAccessSupport to learn more.

Please click here for the Full Prescribing Information and Medication Guide.

About AbbVie
AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas including immunology, neuroscience and oncology – and products and services in our Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on LinkedIn, Facebook, Instagram, X and YouTube.

About AbbVie in Immunology 
AbbVie is relentless in our pursuit to redefine the standard of care for patients living with immune-mediated conditions, with the goal of helping them live a life free from the limitations of their disease. For nearly 30 years, AbbVie has led and helped shape the field of immunology through groundbreaking science and trusted medicines. Building on deep expertise across gastroenterology, rheumatology, dermatology and other areas of high unmet need, we continue to invest in a broad and differentiated pipeline – spanning innovative modalities, novel mechanisms of action and next-generation approaches designed to conquer the complex biology underlying immune-mediated disease.

Today, more than 1 million patients worldwide are treated with AbbVie's immunology medicines, approved in more than 175 countries across 20+ immune-mediated diseases that impact adult and pediatric populations. As we work to strengthen our legacy and drive the next wave of innovation, we remain focused on delivering meaningful progress for patients and expanding access to our medicines. For more information, please visit www.abbvie.com/immunology.

Forward-Looking Statements
Some statements in this news release are, or may be considered, forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. The words "believe," "expect," "anticipate," "project" and similar expressions and uses of future or conditional verbs, generally identify forward-looking statements. AbbVie cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those expressed or implied in the forward-looking statements. Such risks and uncertainties include, but are not limited to, challenges to intellectual property, competition from other products, difficulties inherent in the research and development process, adverse litigation or government action, changes to laws and regulations applicable to our industry, the impact of global macroeconomic factors, such as economic downturns or uncertainty, international conflict, trade disputes and tariffs, and other uncertainties and risks associated with global business operations. Additional information about the economic, competitive, governmental, technological and other factors that may affect AbbVie's operations is set forth in Item 1A, "Risk Factors," of AbbVie's 2025 Annual Report on Form 10-K, which has been filed with the Securities and Exchange Commission, as updated by its Quarterly Reports on Form 10-Q and in other documents that AbbVie subsequently files with the Securities and Exchange Commission that update, supplement or supersede such information. AbbVie undertakes no obligation, and specifically declines, to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law. 

References: 
i. Co-primary endpoint defined as Crohn's Disease Activity Index (CDAI) score <150.
ii. Co-primary endpoint defined as decrease in SES-CD > 50% from baseline (or for patients with isolated ileal disease and a baseline SES-CD of 4, at least a 2-point reduction from baseline), as scored by a central reviewer.
iii. SKYRIZI [Package Insert]. North Chicago, IL: AbbVie Inc. 
iv. Defined as CDAI of 220 to 450 and SES-CD ≥ 6 (or ≥ 4 for isolated ileal disease).
v. Keefer L, Griffith JM, Yang M, et al. Treatment satisfaction and patients' experiences with risankizumab on-body injector among adults with Crohn's disease in clinical practice: initial results from the ASPIRE-CD study. Poster P5425. Presented at: American College of Gastroenterology Annual Scientific Meeting; October 24-29, 2025; Phoenix, AZ. 
vi. Data on file, AbbVie Inc. Source: ZS Associates; December 2024-February 2025.
vii. Crohn's & Colitis Foundation. The facts about inflammatory bowel diseases. Crohn's & Colitis Foundation. Published November 2014. Accessed October 13, 2026. https://www.crohnscolitisfoundation.org/sites/default/files/2019-02/Updated%20IBD%20Factbook.pdf.
viii. Mayo Clinic. Crohn's disease - Symptoms and causes. Mayo Clinic. Accessed February 23, 2026. https://www.mayoclinic.org/diseases-conditions/crohns-disease/symptoms-causes/syc-20353304.
ix. Mehta F. Report: economic implications of inflammatory bowel disease and its management. Am J Manag Care. 2016 Mar;22(3 Suppl):s51-60.
x. Kaplan G. The global burden of IBD: from 2015 to 2025. Nat Rev Gastroenterol Hepatol. 2015 Dec;12(12):720-7. doi: 10.1038/nrgastro.2015.150.
xi. Gajendran M, et al. A comprehensive review and update on Crohn's disease. Dis Mon. 2018 Feb;64(2):20-57. doi: 10.1016/j.disamonth.2017.07.001.
xii. ClinicalTrials.gov. A Study to Evaluate Efficacy and Safety of Risankizumab Subcutaneous Induction in Participants With Moderately to Severely Active Crohn's Disease (AFFIRM). NCT06063967. Available at: https://clinicaltrials.gov/study/NCT06063967. Accessed October 13, 2026.

SOURCE AbbVie

The market expects AbbVie (ABBV - Free Report) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended September 2026. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence its near-term stock price is how the actual results compare to these estimates.

The earnings report, which is expected to be released on October 30, might help the stock move higher if these key numbers are better than expectations. On the other hand, if they miss, the stock may move lower.

While the sustainability of the immediate price change and future earnings expectations will mostly depend on management's discussion of business conditions on the earnings call, it's worth handicapping the probability of a positive EPS surprise.

Zacks Consensus EstimateThis drugmaker is expected to post quarterly earnings of $3.79 per share in its upcoming report, which represents a year-over-year change of +103.8%.

Revenues are expected to be $17.37 billion, up 10.1% from the year-ago quarter.

Estimate Revisions TrendThe consensus EPS estimate for the quarter has been revised 1.35% lower over the last 30 days to the current level. This is essentially a reflection of how the covering analysts have collectively reassessed their initial estimates over this period.

Investors should keep in mind that the direction of estimate revisions by each of the covering analysts may not always get reflected in the aggregate change.

Price, Consensus and EPS Surprise

Earnings WhisperEstimate revisions ahead of a company's earnings release offer clues to the business conditions for the period whose results are coming out. This insight is at the core of our proprietary surprise prediction model -- the Zacks Earnings ESP (Expected Surprise Prediction).

The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter; the Most Accurate Estimate is a more recent version of the Zacks Consensus EPS estimate. The idea here is that analysts revising their estimates right before an earnings release have the latest information, which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier.

Thus, a positive or negative Earnings ESP reading theoretically indicates the likely deviation of the actual earnings from the consensus estimate. However, the model's predictive power is significant for positive ESP readings only.

A positive Earnings ESP is a strong predictor of an earnings beat, particularly when combined with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold). Our research shows that stocks with this combination produce a positive surprise nearly 70% of the time, and a solid Zacks Rank actually increases the predictive power of Earnings ESP.

Please note that a negative Earnings ESP reading is not indicative of an earnings miss. Our research shows that it is difficult to predict an earnings beat with any degree of confidence for stocks with negative Earnings ESP readings and/or Zacks Rank of 4 (Sell) or 5 (Strong Sell).

How Have the Numbers Shaped Up for AbbVie?For AbbVie, the Most Accurate Estimate is lower than the Zacks Consensus Estimate, suggesting that analysts have recently become bearish on the company's earnings prospects. This has resulted in an Earnings ESP of -0.26%.

On the other hand, the stock currently carries a Zacks Rank of #4.

So, this combination makes it difficult to conclusively predict that AbbVie will beat the consensus EPS estimate.

Does Earnings Surprise History Hold Any Clue?Analysts often consider to what extent a company has been able to match consensus estimates in the past while calculating their estimates for its future earnings. So, it's worth taking a look at the surprise history for gauging its influence on the upcoming number.

For the last reported quarter, it was expected that AbbVie would post earnings of $3.64 per share when it actually produced earnings of $3.65, delivering a surprise of +0.27%.

Over the last four quarters, the company has beaten consensus EPS estimates four times.

Bottom LineAn earnings beat or miss may not be the sole basis for a stock moving higher or lower. Many stocks end up losing ground despite an earnings beat due to other factors that disappoint investors. Similarly, unforeseen catalysts help a number of stocks gain despite an earnings miss.

That said, betting on stocks that are expected to beat earnings expectations does increase the odds of success. This is why it's worth checking a company's Earnings ESP and Zacks Rank ahead of its quarterly release. Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they've reported.

AbbVie doesn't appear a compelling earnings-beat candidate. However, investors should pay attention to other factors too for betting on this stock or staying away from it ahead of its earnings release.

An Industry Player's Expected ResultsAnother stock from the Zacks Large Cap Pharmaceuticals industry, Eli Lilly (LLY - Free Report) , is soon expected to post earnings of $5.38 per share for the quarter ended September 2026. This estimate indicates a year-over-year change of -23.4%. Revenues for the quarter are expected to be $22.11 billion, up 25.6% from the year-ago quarter.

The consensus EPS estimate for Lilly has been revised 0.1% higher over the last 30 days to the current level. However, an equal Most Accurate Estimate has resulted in an Earnings ESP of 0.00%.

This Earnings ESP, combined with its Zacks Rank #3 (Hold), makes it difficult to conclusively predict that Lilly will beat the consensus EPS estimate. The company beat consensus EPS estimates in each of the trailing four quarters.

Stay on top of upcoming earnings announcements with the Zacks Earnings Calendar.

The pharmaceutical business is capital-intensive at certain stages, but once a pharma company achieves success with a drug, it can become quite the cash generator. The U.S. pharmaceutical sector has numerous companies like this, and with the strong cash flow they generate, they reliably pay generous dividends.

Two of these creatures are Pfizer (PFE +1.91%) and AbbVie (ABBV +0.14%). But in an environment of rising interest rates, the payouts that distinguish them from peer stocks might be more of a hindrance than a help. Here's why.

Image source: Getty Images.

The yield factor The most trusted borrower in the world is the U.S. government, as it issues mountains of debt and has never defaulted on any of it. As a result, its 10-year Treasury note (T-note) is considered to be the global benchmark bond, given the considerable financial strength and consistency of its issuer.

Because of this, it's the one bond against which other debt instruments are compared. Its yield is used not only to compare returns on debt but also other types of returns, such as dividends.

All things being equal, a dividend-paying stock's yield should at least be somewhat competitive with current bond yields. For many investors, a choice income stock marries an attractive yield with an underlying business that can still produce growth.

The single largest influence on bonds is the federal funds target rate (actually, a range) set by the U.S. Federal Reserve. Generally speaking, higher rates translate to higher yields.

Following a series of cuts by the Fed in 2024 and 2025, last month it enacted a widely expected increase (of 25 basis points). This was, of course, an attempt to cool inflation, which remains persistent and could very well continue to be.

PFE Pfizer$30.42+$0.57 (+1.91%)

NYSE · As of 4:00 PM ET 10/22/26

Rising rates That's why numerous economists and analysts expect further Fed rate hikes in the coming months. When and if that happens, many investors will cast an increasingly wary eye on the dividend yields of businesses like Pfizer and AbbVie.

Again, the difference between a static yield-producing instrument like a T-note and a productive business is considerable, so dividend yield isn't a be-all and end-all. The takeaway here is that said business needs to genuinely be productive, i.e., grow, for any yield gap to be insignificant.

I'd say Pfizer isn't at this stage now, while AbbVie is. Pfizer has several top products approaching the dreaded patent cliff and has largely addressed this by making acquisitions and beefing up its development program. While it's essentially in this reset mode, the trajectory of its fundamentals hasn't been impressive; many investors are probably hanging on for that chunky yield, which is currently 5.7%.

AbbVie, with a dividend yield of 2.4%, is a different story. One reason for that comparatively far lower yield is the popularity of its stock. This, in turn, is largely due to the emergence of two blockbuster drugs (Skyrizi and Rinvoq) making up for the loss of exclusivity for another, Humira. Sales of other products in the portfolio are growing robustly, as are the company's overall fundamentals.

Ultimately, then, I think rising rates will put more pressure on Pfizer's stock than AbbVie's. I'm actually bullish on both. I would predict, though, that the former's turnaround will be slow, so it might be a suitable buy only for long-term-focused investors.

Capstone Capital Management Ltd bought a new stake in AbbVie Inc. (NYSE:ABBV – Free Report) in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm bought 3,772 shares of the company’s stock, valued at approximately $987,000.

Several other hedge funds have also bought and sold shares of the company. Range Financial Group LLC raised its stake in AbbVie by 2.4% in the 3rd quarter. Range Financial Group LLC now owns 5,565 shares of the company’s stock valued at $1,456,000 after acquiring an additional 130 shares during the period. Newman Dignan & Sheerar Inc. boosted its position in AbbVie by 57.9% during the third quarter. Newman Dignan & Sheerar Inc. now owns 6,547 shares of the company’s stock worth $1,713,000 after purchasing an additional 2,400 shares during the period. Benchmark Financial Wealth Advisors LLC boosted its position in AbbVie by 11.0% during the third quarter. Benchmark Financial Wealth Advisors LLC now owns 4,309 shares of the company’s stock worth $1,127,000 after purchasing an additional 428 shares during the period. Cushing Capital Partners LLC bought a new position in AbbVie during the third quarter worth $242,000. Finally, Physician Wealth Advisors Inc. increased its holdings in shares of AbbVie by 11.3% in the third quarter. Physician Wealth Advisors Inc. now owns 1,531 shares of the company’s stock valued at $401,000 after purchasing an additional 155 shares during the last quarter. 70.23% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity In other news, EVP Nicholas Donoghoe sold 32,710 shares of the business’s stock in a transaction dated Friday, August 14th. The shares were sold at an average price of $250.00, for a total value of $8,177,500.00. Following the completion of the sale, the executive vice president owned 74,430 shares of the company’s stock, valued at approximately $18,607,500. The trade was a 30.53% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders own 0.06% of the company’s stock.

AbbVie Trading Down 1.5% NYSE:ABBV opened at $284.63 on Thursday. The stock has a market cap of $502.89 billion, a P/E ratio of 80.41, a PEG ratio of 1.32 and a beta of 0.24. The stock has a 50 day simple moving average of $264.93 and a 200 day simple moving average of $240.92. AbbVie Inc. has a 1-year low of $190.75 and a 1-year high of $291.40. AbbVie (NYSE:ABBV – Get Free Report) last released its quarterly earnings results on Friday, July 31st. The company reported $3.65 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.61 by $0.04. AbbVie had a negative return on equity of 422.07% and a net margin of 9.80%. The business had revenue of $16.99 billion during the quarter, compared to the consensus estimate of $16.80 billion. During the same period in the previous year, the company posted $2.97 EPS. The firm’s quarterly revenue was up 10.2% on a year-over-year basis. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. As a group, sell-side analysts forecast that AbbVie Inc. will post 13.94 EPS for the current year.

AbbVie Announces Dividend The firm also recently announced a quarterly dividend, which will be paid on Monday, November 16th. Stockholders of record on Thursday, October 15th will be given a $1.73 dividend. This represents a $6.92 dividend on an annualized basis and a dividend yield of 2.4%. The ex-dividend date of this dividend is Thursday, October 15th. AbbVie’s payout ratio is presently 195.48%.

AbbVie News Summary Here are the key news stories impacting AbbVie this week:

Positive Sentiment: AbbVie reported encouraging Phase 2a data for ABBV-466, an investigational combination treatment for Crohn’s disease. The therapy reportedly outperformed Skyrizi alone, strengthening the company’s immunology pipeline and helping offset concerns about the eventual loss of exclusivity for Humira. AbbVie’s Crohn’s Combo Topped Skyrizi Alone in a Phase 2a Trial Positive Sentiment: Allergan Aesthetics, AbbVie’s aesthetics business, presented new and long-term evidence for HArmonyCa, JUVÉDERM, SKINVIVE and BOTOX Cosmetic. Continued product adoption and clinical support could aid growth in the aesthetics segment. Allergan Aesthetics Deepens Science Behind Multimodal Approach Positive Sentiment: The company launched a multiyear partnership with McLaren Racing, including the “AbbVie Race to Innovate” patient-advocacy campaign. The agreement is primarily a branding initiative, but it may increase awareness of AbbVie’s immunology franchise. McLaren Racing Announces Partnership With AbbVie Neutral Sentiment: Analyst comparisons continue to highlight AbbVie’s revenue growth, strong free cash flow and dependable dividend increases. However, the stock’s elevated valuation after its rally leaves less room for disappointment. Negative Sentiment: AbbVie halted a Phase 1b combination trial for early-stage liver cancer. Because the study was in an early development stage, the direct financial impact may be limited, but the decision removes a potential pipeline opportunity and likely weighed on sentiment. AbbVie Halts Early-Stage Liver Cancer Combo Trial Analyst Upgrades and Downgrades Several equities analysts have recently weighed in on the stock. Cantor Fitzgerald increased their price objective on shares of AbbVie from $285.00 to $290.00 and gave the company an “overweight” rating in a research report on Thursday, October 8th. Argus raised their target price on shares of AbbVie from $250.00 to $270.00 in a research note on Tuesday, August 4th. Piper Sandler lifted their target price on shares of AbbVie from $298.00 to $303.00 and gave the stock an “overweight” rating in a report on Thursday, August 20th. Rothschild & Co Redburn upped their price target on shares of AbbVie from $284.00 to $285.00 and gave the company a “buy” rating in a research note on Tuesday, August 4th. Finally, Royal Bank Of Canada reiterated an “outperform” rating and issued a $280.00 price target on shares of AbbVie in a research note on Tuesday, October 13th. One analyst has rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and six have given a Hold rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $278.07.

Read Our Latest Stock Analysis on AbbVie

About AbbVie (Free Report)

AbbVie Inc (NYSE: ABBV) is a global biopharmaceutical company that discovers, develops and commercializes medicines and other healthcare products. Its portfolio focuses on immunology, oncology, neuroscience, aesthetics and eye care, serving patients and healthcare providers in markets around the world.

The company’s key products include immunology medicines such as Skyrizi and Rinvoq; neuroscience treatments including Vraylar, Ubrelvy and Qulipta; and oncology products such as Imbruvica and Venclexta.

See Also Five stocks we like better than AbbVie GM Beat and Added a $20 Billion Buyback—Why Did the Stock Fall? Intercepting Growth: Karman Secures $218M Lockheed Martin Deal Tech Stocks Took a Hit—These 2 Pharma Stocks Are Near New Highs Chip Stocks Have Pulled Back—Here’s How 3 Semiconductor ETFs Stack Up for Investors

Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with MarketBeat.com's FREE daily email newsletter.

In the Phase 3 INTREPID study, lutikizumab achieved the primary endpoint of Hidradenitis Suppurativa Clinical Response 75 (HiSCR75) at Week 16 compared with placebo1 Lutikizumab met 8 ranked secondary endpoints, including significant improvements in HS-related skin pain at Week 8 and significant reductions in the occurrence of HS flares over the first 16 weeks,1 reflecting outcomes assessed by both patients and physicians Lutikizumab was generally well tolerated, with no new safety concerns identified1 INTREPID provides Phase 3 data supporting the continued investigation of simultaneous inhibition of IL-1α and IL-1β as a potential treatment approach in adults and adolescents with moderate to severe HS1 NORTH CHICAGO, Ill., Oct. 22, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced positive topline results from the Phase 3 INTREPID study evaluating the safety and efficacy of lutikizumab, an investigational dual-variable-domain interleukin (IL) 1α/1β antagonist, in adults and adolescents with moderate to severe hidradenitis suppurativa (HS).

In the Phase 3 INTREPID study, lutikizumab achieved the primary endpoint of Hidradenitis Suppurativa Clinical Response 75 (HiSCR75) at Week 16 compared with placebo1Lutikizumab met 8 ranked secondary endpoints, including significant improvements in HS-related skin pain at Week 8 and significant reductions in the occurrence of HS flares over the first 16 weeks,1 reflecting outcomes assessed by both patients and physiciansLutikizumab was generally well tolerated, with no new safety concerns identified1INTREPID provides Phase 3 data supporting the continued investigation of simultaneous inhibition of IL-1α and IL-1β as a potential treatment approach in adults and adolescents with moderate to severe HS1, /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced positive topline results from the Phase 3 INTREPID study evaluating the safety and efficacy of lutikizumab, an investigational dual-variable-domain interleukin (IL) 1α/1β antagonist, in adults and adolescents with moderate to severe hidradenitis suppurativa (HS). The study met its primary endpoint and 8 ranked secondary endpoints.

In the INTREPID study, patients treated with lutikizumab achieved significantly higher response rates for the primary endpoint of HiSCR75 at Week 16 compared with placebo (31.4% versus 23.4%; p≤0.001). HiSCR75 is defined as at least a 75% reduction from baseline in the total abscess and inflammatory nodule (AN) count, with no increase in abscess count and no increase in draining fistula count relative to baseline. INTREPID is the first phase 3 study including adults and adolescents with HS to demonstrate statistically significant HiSCR75 response rates at Week 16 as the primary endpoint.

Lutikizumab also demonstrated statistically significant improvements across key ranked secondary endpoints, including rapid reductions in HS-related pain and significantly fewer HS flares, compared to placebo. At Week 8, 26.2% of patients treated with lutikizumab achieved NRS3, defined as at least a 3-point reduction from baseline in HS-related skin pain on the Numeric Rating Scale (NRS), compared with 15.0% of patients receiving placebo (p1

Additional improvements were observed in quality-of-life measures, including changes from baseline in the dermatology life quality index (DLQI) and hidradenitis suppurativa impact assessment (HSIA) (p

"Elevated levels of IL-1α and IL-1β have been identified in HS lesions, supporting the mechanistic rationale for evaluating lutikizumab in HS. These results further validate our science-led approach and demonstrate how AbbVie applies its deep immunology expertise in our efforts to advance potentially differentiated new treatments grounded in disease biology," said Kori Wallace, M.D., vice president, global head of immunology clinical development, AbbVie. "In addition to achieving the rigorous bar set by HiSCR75, lutikizumab also significantly improved HS-related skin pain and disease flares, reinforcing the importance of an approach to HS that addresses outcomes assessed by both physicians and most importantly, patients."

The safety profile of lutikizumab was similar to prior studies, with no new safety concerns identified. Overall, treatment-emergent adverse event (TEAE) rates were similar with lutikizumab and placebo: any adverse event (AE) (53.4% vs 53.7%), any serious AE (3.0% vs 2.9%), and AEs leading to discontinuation (1.7% vs 1.9%), respectively. The most frequently reported TEAEs associated with lutikizumab (≥ 3%) were nasopharyngitis, upper respiratory tract infections, headache, fatigue, and injection-site reactions. With the exception of injection-site reactions, their rates were similar to placebo. Similar rates of oral candidiasis were also observed between the lutikizumab and placebo groups (0.3% vs 0.4%, respectively). There was no suicidal ideation observed in either the lutikizumab or placebo group. There were no deaths in the lutikizumab group; one death occurred in the placebo group.

"Hidradenitis suppurativa remains an underserved disease and many patients continue to struggle with pain and disease flares despite available therapies," said Alexa B. Kimball, M.D., M.P.H., President and CEO of Harvard Medical Faculty Physicians at Beth Israel Deaconess Medical Center, Boston, and Professor of Dermatology at Harvard Medical School. "The INTREPID data are notable because the primary endpoint of HiSCR75 sets a rigorous bar for defining clinical response. These are also the first Phase 3 data evaluating the effect of targeting both IL-1α and IL-1β on this disease. Taken together, these results underscore the promising potential of this investigational treatment."

These data will be presented at a future medical congress. Additional data from the Phase 3 INTREPID study, including results from a 36-week blinded extension period, are expected in 2027 and will be used to support regulatory submissions for lutikizumab in hidradenitis suppurativa in the second half of the year.

These Phase 3 results for lutikizumab reinforce AbbVie's commitment to advancing innovation in hidradenitis suppurativa. Through its HS platform study program, expected to begin later this year, AbbVie plans to evaluate lutikizumab in combination with ABBV-295 (long-acting amylin analog) and potentially other complementary mechanisms, including ABBV-701 (anti-TL1A monoclonal antibody), to address multiple disease pathways that may improve outcomes for patients living with HS.

About the INTREPID Study
INTREPID is a Phase 3 multicenter, randomized, double-blind placebo-controlled study to evaluate the efficacy and safety of lutikizumab in adults and adolescents with moderate to severe hidradenitis suppurativa.2 The primary endpoint, achievement of HiSCR75 at Week 16, is defined as at least a 75% reduction from baseline in the total abscess and inflammatory nodule (AN) count, with no increase in abscess count and no increase in draining fistula count relative to baseline.2 One of the key secondary endpoints, achievement of NRS30 at Week 8, is defined as at least a 30% reduction and at least a 2-unit reduction from baseline in worst skin pain (maximal daily pain) among subjects with NRS ≥3 at baseline, as assessed by the Patient's Global Assessment (PGA) of HS-related skin Pain NRS.2 Another key secondary endpoint, achievement of NRS3 at Week 8, is defined as at least a 3-unit reduction from baseline in worst skin pain (maximal daily pain) among subjects with NRS ≥3 at baseline, as assessed by the PGA of HS-related skin pain NRS.2 Another key secondary endpoint, occurrence of HS flare during the first 16 weeks, was defined as at least one occurrence of a ≥25% increase in AN count with a minimum absolute increase of 2 relative to baseline.2 A total of 1400 patients were randomized, globally, across North America, South America, Europe and Asia, in a 1:1 ratio to lutikizumab SC or placebo. The study consists of three treatment periods: a placebo-controlled Period 1 (baseline to Week 16) to evaluate the efficacy and safety of lutikizumab, a Period 2 (Week 16 to 52) where patients receive blinded lutikizumab, and a 156-week long-term extension Period 3 where all patients continue to receive lutikizumab. The primary and ranked secondary endpoints were evaluated using a prespecified graphical testing approach to control the overall type I error rate. Additional information about the program can be found on clinicaltrials.gov under the identifier NCT06468228.

About Hidradenitis Suppurativa
Hidradenitis suppurativa is a chronic, recurrent, inflammatory and progressive disease that causes irreversible skin damage and disability due to the formation of painful cysts, abscesses and draining fistulas.3,4,5,6,7 While advances in treatment have been made, limited treatment options are available. Globally, HS affects approximately 1 percent of the population8 and can take on average 7-10 years for a person to be diagnosed.9,10

About Lutikizumab (ABT-981)
Lutikizumab (ABT-981) is a dual-variable-domain interleukin (IL) 1α/1β antagonist being investigated in HS. Studies have shown that IL-1α and IL-1β are elevated in HS lesions.11 Lutikizumab is an investigational agent and is not approved by regulatory authorities. Safety and efficacy have not been established.

About AbbVie in Immunology
AbbVie is relentless in our pursuit to redefine the standard of care for patients living with immune-mediated conditions, with the goal of helping them live a life free from the limitations of their disease. For almost 30 years, AbbVie has led and helped shape the field of immunology through groundbreaking science and trusted medicines. Building on deep expertise across gastroenterology, rheumatology, dermatology and other areas of high unmet need, we continue to invest in a broad and differentiated pipeline – spanning innovative modalities, novel mechanisms of action and next-generation approaches designed to conquer the complex biology underlying immune-mediated disease.

Today, more than 1 million patients worldwide are treated with AbbVie's immunology medicines, approved in more than 175 countries across 20+ immune-mediated diseases that impact adult and pediatric populations. As we work to strengthen our legacy and drive the next wave of innovation, we remain focused on delivering meaningful progress for patients and expanding access to our medicines. For more information, please visit www.abbvie.com/immunology.

About AbbVie
AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas including immunology, neuroscience and oncology – and products and services in our Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on LinkedIn, Facebook, Instagram, X and YouTube.

Dr. Kimball is a consultant for AbbVie.

Forward-Looking Statements
Some statements in this news release are, or may be considered, forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. The words "believe," "expect," "anticipate," "project" and similar expressions and uses of future or conditional verbs, generally identify forward-looking statements. AbbVie cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those expressed or implied in the forward-looking statements. Such risks and uncertainties include, but are not limited to, challenges to intellectual property, competition from other products, difficulties inherent in the research and development process, adverse litigation or government action, changes to laws and regulations applicable to our industry, the impact of global macroeconomic factors, such as economic downturns or uncertainty, international conflict, trade disputes and tariffs, and other uncertainties and risks associated with global business operations. Additional information about the economic, competitive, governmental, technological and other factors that may affect AbbVie's operations is set forth in Item 1A, "Risk Factors," of AbbVie's 2025 Annual Report on Form 10-K, which has been filed with the Securities and Exchange Commission, as updated by its Quarterly Reports on Form 10-Q and in other documents that AbbVie subsequently files with the Securities and Exchange Commission that update, supplement or supersede such information. AbbVie undertakes no obligation, and specifically declines, to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.

References
1 AbbVie Data on File ABVRRTI83883.
2 A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa (Intrepid). ClinicalTrials.gov. Available at: https://clinicaltrials.gov/study/NCT06468228. Accessed September 29, 2026.
3 Negus D, Ahn C, Huang W. An update on the pathogenesis of hidradenitis suppurativa: implications for therapy. Expert Rev Clin Immunol. 2018;14(4):275-283.
4 Patel ZS et al. Pain, Psychological Comorbidities, Disability, and Impaired Quality of Life in Hidradenitis Suppurativa [corrected]. Curr Pain Headache Rep. 2017;21(12):49.
5 Chen WT, et al. JAMA Dermatol. 2019 Jul 10.
6 Jemec G. Hidradenitis Suppurativa. N Engl J Med. 2012; 366:158-64.
7 Kimball A, et al. Two Phase 3 Trials of Adalimumab for Hidradenitis Suppurativa. New England Journal of Medicine 375.5; 2016: 422-34.
8 Egeberg A, et al. JAMA Dermatol 2016;152:429–34.
9 Garg A, et al. JAMA Dermatol. 2018 Jul 1;154(7):814-818.
10 Saunte DM, et al. Br J Dermatol 2015;173:1546–9.
11 VanderZee et al British Journal of Dermatology (2011) 164, p1292–98; Kanni et al (2015) PLoS ONE 10(6): e0130522.

View original content:https://www.prnewswire.com/news-releases/abbvie-announces-topline-results-from-the-phase-3-intrepid-trial-showing-lutikizumab-significantly-improved-signs-and-symptoms-of-disease-in-patients-with-hidradenitis-suppurativa-302915895.html

SOURCE AbbVie

Axxcess Wealth Management LLC decreased its holdings in AbbVie Inc. (NYSE:ABBV – Free Report) by 45.1% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 48,309 shares of the company’s stock after selling 39,607 shares during the period. Axxcess Wealth Management LLC’s holdings in AbbVie were worth $12,637,000 as of its most recent SEC filing.

Other hedge funds have also made changes to their positions in the company. Ranch Capital Advisors Inc. increased its stake in shares of AbbVie by 37.0% in the first quarter. Ranch Capital Advisors Inc. now owns 14,888 shares of the company’s stock worth $3,238,000 after acquiring an additional 4,017 shares during the last quarter. Capital Advisors Inc. OK increased its position in AbbVie by 11.2% in the 2nd quarter. Capital Advisors Inc. OK now owns 447,129 shares of the company’s stock worth $112,516,000 after purchasing an additional 45,132 shares during the last quarter. Danica Pension Livsforsikringsaktieselskab purchased a new stake in shares of AbbVie during the 2nd quarter worth about $23,557,000. Wedge Capital Management L L P NC raised its stake in shares of AbbVie by 7.5% during the 2nd quarter. Wedge Capital Management L L P NC now owns 134,579 shares of the company’s stock worth $33,865,000 after purchasing an additional 9,380 shares in the last quarter. Finally, State Street Corp raised its stake in shares of AbbVie by 1.7% during the 2nd quarter. State Street Corp now owns 82,596,748 shares of the company’s stock worth $20,784,646,000 after purchasing an additional 1,379,232 shares in the last quarter. 70.23% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth ABBV has been the subject of several recent research reports. Citigroup boosted their price target on AbbVie from $230.00 to $260.00 and gave the company a “neutral” rating in a research note on Wednesday, July 15th. BNP Paribas Exane raised their price objective on shares of AbbVie from $218.00 to $247.00 and gave the company a “neutral” rating in a research report on Tuesday, August 11th. UBS Group raised their price objective on shares of AbbVie from $260.00 to $275.00 and gave the company a “neutral” rating in a research report on Tuesday, October 6th. Bank of America reiterated a “buy” rating on shares of AbbVie in a research note on Tuesday, September 8th. Finally, Canaccord Genuity Group boosted their target price on shares of AbbVie from $282.00 to $290.00 and gave the stock a “buy” rating in a research report on Monday, August 3rd. One equities research analyst has rated the stock with a Strong Buy rating, twenty-three have given a Buy rating and six have assigned a Hold rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $278.07.

Get Our Latest Stock Analysis on ABBV AbbVie News Summary Here are the key news stories impacting AbbVie this week:

Positive Sentiment: AbbVie reported encouraging Phase 2a data for ABBV-466, an investigational combination treatment for Crohn’s disease. The therapy reportedly outperformed Skyrizi alone, strengthening the company’s immunology pipeline and helping offset concerns about the eventual loss of exclusivity for Humira. AbbVie’s Crohn’s Combo Topped Skyrizi Alone in a Phase 2a Trial Positive Sentiment: Allergan Aesthetics, AbbVie’s aesthetics business, presented new and long-term evidence for HArmonyCa, JUVÉDERM, SKINVIVE and BOTOX Cosmetic. Continued product adoption and clinical support could aid growth in the aesthetics segment. Allergan Aesthetics Deepens Science Behind Multimodal Approach Positive Sentiment: The company launched a multiyear partnership with McLaren Racing, including the “AbbVie Race to Innovate” patient-advocacy campaign. The agreement is primarily a branding initiative, but it may increase awareness of AbbVie’s immunology franchise. McLaren Racing Announces Partnership With AbbVie Neutral Sentiment: Analyst comparisons continue to highlight AbbVie’s revenue growth, strong free cash flow and dependable dividend increases. However, the stock’s elevated valuation after its rally leaves less room for disappointment. Negative Sentiment: AbbVie halted a Phase 1b combination trial for early-stage liver cancer. Because the study was in an early development stage, the direct financial impact may be limited, but the decision removes a potential pipeline opportunity and likely weighed on sentiment. AbbVie Halts Early-Stage Liver Cancer Combo Trial Insider Activity at AbbVie In other news, EVP Nicholas Donoghoe sold 32,710 shares of the business’s stock in a transaction on Friday, August 14th. The shares were sold at an average price of $250.00, for a total value of $8,177,500.00. Following the completion of the sale, the executive vice president directly owned 74,430 shares in the company, valued at approximately $18,607,500. The trade was a 30.53% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 0.06% of the stock is currently owned by corporate insiders.

AbbVie Stock Performance Shares of NYSE ABBV opened at $284.63 on Thursday. The firm has a market cap of $502.89 billion, a price-to-earnings ratio of 80.41, a P/E/G ratio of 1.32 and a beta of 0.24. The business’s 50-day simple moving average is $264.93 and its 200-day simple moving average is $240.92. AbbVie Inc. has a 52 week low of $190.75 and a 52 week high of $291.40.

AbbVie (NYSE:ABBV – Get Free Report) last issued its quarterly earnings data on Friday, July 31st. The company reported $3.65 earnings per share for the quarter, beating analysts’ consensus estimates of $3.61 by $0.04. AbbVie had a negative return on equity of 422.07% and a net margin of 9.80%. The business had revenue of $16.99 billion for the quarter, compared to the consensus estimate of $16.80 billion. During the same period last year, the business earned $2.97 EPS. The firm’s revenue was up 10.2% compared to the same quarter last year. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. As a group, equities research analysts forecast that AbbVie Inc. will post 13.94 earnings per share for the current year.

AbbVie Announces Dividend The company also recently declared a quarterly dividend, which will be paid on Monday, November 16th. Stockholders of record on Thursday, October 15th will be given a $1.73 dividend. The ex-dividend date of this dividend is Thursday, October 15th. This represents a $6.92 dividend on an annualized basis and a dividend yield of 2.4%. AbbVie’s dividend payout ratio (DPR) is currently 195.48%.

About AbbVie (Free Report)

AbbVie Inc (NYSE: ABBV) is a global biopharmaceutical company that discovers, develops and commercializes medicines and other healthcare products. Its portfolio focuses on immunology, oncology, neuroscience, aesthetics and eye care, serving patients and healthcare providers in markets around the world.

The company’s key products include immunology medicines such as Skyrizi and Rinvoq; neuroscience treatments including Vraylar, Ubrelvy and Qulipta; and oncology products such as Imbruvica and Venclexta.

Featured Stories Five stocks we like better than AbbVie GM Beat and Added a $20 Billion Buyback—Why Did the Stock Fall? Intercepting Growth: Karman Secures $218M Lockheed Martin Deal Tech Stocks Took a Hit—These 2 Pharma Stocks Are Near New Highs Chip Stocks Have Pulled Back—Here’s How 3 Semiconductor ETFs Stack Up for Investors

Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with MarketBeat.com's FREE daily email newsletter.

Allergan Aesthetics will present eight scientific posters featuring new and long-term evidence across HArmonyCa™, JUVÉDERM®, SKINVIVE™ and BOTOX® Cosmetic
The latest HArmonyCa™ data reinforces its dual-action technology, supported by long-term clinical efficacy data and new findings in patients undergoing medical weight loss
The company will also host a series of events and educational activities, including a symposium highlighting its global portfolio approach to treatment with AA Signature™

, /PRNewswire/ -- Allergan Aesthetics, an AbbVie company (NYSE: ABBV) and a global leader in aesthetics, will showcase the latest scientific evidence and clinical education supporting its expanding global aesthetics portfolio at the Aesthetic & Anti-Aging Medicine World Congress (AMWC) Dubai, taking place October 21-23, 2026.

The program includes an expert-led symposium hosted by the Allergan Medical Institute (AMI), a global medical affairs symposium and multiple Meet the Expert sessions. Global and regional faculty will discuss the clinical evidence informing the AA Signature™ approach, which integrates treatments from across the Allergan Aesthetics portfolio into personalized treatment planning. The program will focus particularly on AA Signature™ Lift-Up and the introduction of HArmonyCa™ in the United Arab Emirates (UAE).

Following its recent launch in the UAE, HArmonyCa™, a hybrid facial injectable combining hyaluronic acid (HA) and calcium hydroxyapatite (CaHA), will be featured at AMWC Dubai. Developed by Allergan Aesthetics, HArmonyCa™ is a regenerative biostimulator powered by DART® (Dual Action Rejuvenating Technology), combining the immediate lifting effect of HA with the longer-term biostimulatory activity of CaHA.1

"This meeting brings together the science, clinical expertise and education that continue to shape the aesthetics field in the Middle East and beyond," said Darin Messina, Ph.D., senior vice president, head of aesthetics research and development, AbbVie. "The breadth of data to be presented at AMWC reflects Allergan Aesthetics' commitment to developing evidence-based portfolio approaches to treatment as the industry continues to evolve alongside patient needs. We are excited to introduce HArmonyCa™ and its Dual Action Rejuvenating Technology as part of the continued expansion of our aesthetics portfolio."

Growing evidence behind evolving Allergan Aesthetics portfolio

Data being presented at AMWC Dubai add to the clinical and scientific evidence supporting the Allergan Aesthetics portfolio and the products that form the AA Signature™ multimodal approach, including SKINVIVE™, HArmonyCa™ and BOTOX® Cosmetic (onabotulinumtoxinA).

As patients' aesthetic needs evolve over time, changes associated with medical weight loss can span facial volume, structure and skin quality, reinforcing the importance of personalized assessment and treatment planning that considers the patient more holistically. This research adds to the growing body of evidence investigating the use of the Allergan Aesthetics portfolio in patients navigating the effects of medical weight loss.

In a subgroup analysis of patients using glucagon-like peptide-1 (GLP-1) weight-loss medications, all eight participants treated with HArmonyCa™ showed visible midface improvement at three months, providing an early clinical signal for addressing facial volume changes in this emerging patient population. These findings offer preliminary evidence on the use of HArmonyCa™ in patients experiencing facial volume changes while undergoing GLP-1 medical weight loss.2

Additional clinical data being presented include patient-reported outcomes showing improvement in neck appearance and satisfaction after SKINVIVE™ treatment, alongside new original research examining patient-reported satisfaction, treatment benefits and motivations for retreatment among Middle Eastern patients receiving long-term, repeated BOTOX® Cosmetic treatment for upper facial lines. The majority of patients were satisfied with the effects of long-term repeated treatment upper forehead lines and reported feeling younger as a result of the treatment.4

On October 22, Allergan Aesthetics' global medical affairs team will bring together experts for the "Breakthrough Science in Aesthetics: New Frontiers in Clinical Outcomes and Care" symposium. Together, Dr. Mariola Galazka, Dr. Koenraad De Boulle and Dr. Mansi Mukherjee will discuss advances in neurotoxin science and innovation, long-term BOTOX® Cosmetic evidence and natural-looking outcomes of the portfolio, while highlighting the value of multimodal aesthetic approaches. They will also explore how emerging science can unlock new possibilities for key patient segments and shape the future of aesthetics.

Showcasing educational science

On October 21, AMI will host the "AA Signature™ Lift-Up Multimodal Approach with Regenerative Biostimulation" symposium. Dr. Raafat Lakis, Dr. Reha Yavuzer and Dr. Mariola Galazka will explore the AA Signature™ Lift-Up approach, HArmonyCa™ and DART® Technology as part of longer-term multimodal treatment planning. The program will also feature a live technique showcase and an expert panel discussion.

Practitioners can engage directly with faculty during Meet the Expert sessions at Allergan Aesthetics booth B16, covering the AA Signature™ Lift-Up approach, clinical considerations in facial neurotoxin treatment and the importance of building trust through clinical expertise.

Collectively, the program underscores Allergan Aesthetics' commitment to advancing personalized, evidence-led aesthetics.

Type

Title

Authors

BOTOX® Cosmetic

Original   

Patient-Perceived Satisfaction and Benefits of
Long-Term OnabotulinumtoxinA for Upper
Facial Lines: A Sub-Analysis of Patients From
Middle Eastern Sites From a Global
Retrospective Chart Review and Cross-
Sectional Study

Mukherjee M, Aleisa
AM, Raza A,
Musumeci M

HArmonyCa™

Encore

Complete Analysis of a 24-Month Multicenter,
Evaluator-Blinded, Randomized, Parallel-
Group Study to Evaluate the Safety and
Effectiveness of a Hybrid Hyaluronic Acid and
Calcium Hydroxyapatite Injectable for Midface
Soft Tissue Augmentation

Humphrey S,
Demosthenous N,
Nikolis A, Urdiales
Gálvez F, Salomon M,
Schumacher A

Encore

Treatment of Midface Volume Deficits with a
Hybrid Hyaluronic Acid and Calcium
Hydroxyapatite Injectable in Participants
Undergoing GLP-1 Medical Weight Loss: A
Safety and Efficacy Subgroup Analysis from a
Pivotal Study

Humphrey S, Nikolis
A, Urdiales Gálvez F,
Demosthenous N,
Kus S, Kerson G,
Salomon M,
Schumacher A

Encore

An Evaluation of the Mechanism of Action of a
Hyaluronic Acid and Calcium Hydroxyapatite
Hybrid Injectable

Braz A, Chang N,
Urdiales Gálvez F,
Hariri S, Malkah N,
Nakab L

JUVÉDERM®/HA fillers

Encore

Patient Reported Satisfaction and Improvement
of Neck Appearance with VYC-12L: Results
From a Multicenter, Evaluator-Blinded,
Randomized, Controlled Study

Cox SE, Palm M,
Burgess C, Kazin R,
Nguyen T, Garcia JK,
Chawla S

Encore

Cross-linked Hyaluronic Acid Gel's Secondary
Effects on Dermal ECM Structure and Stability:
A Spatial Proteomics Study

Kutikov A, Pierce A,
Malkah N, Nakab L

Encore

Assessing the Potential for Injectable HA Gel
Displacement: A 3D Imaging Study in a Rat
Model

Pierce A, Ly J, Nakab
L, Kutikov A

Encore

Evaluation of Degradation Kinetics and
Biocompatibility of VYC-20L HA Dermal Filler in
a Rodent Model Using MRI and Histological
Analysis

Kutikov A, Nakab L

About Allergan Aesthetics

At Allergan Aesthetics, an AbbVie company, we develop, manufacture, and market a portfolio of leading aesthetics brands and products. Our aesthetics portfolio includes facial injectables, body contouring, plastics, skin care, and more. Our goal is to consistently provide our customers with innovation, education, exceptional service, and a commitment to excellence, all with a personal touch. For more information, visit www.allerganaesthetics.com.

About AbbVie

AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas including immunology, neuroscience and oncology – and products and services in our Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on LinkedIn, Facebook, Instagram, X and YouTube.

Forward-Looking Statements

Some statements in this news release are, or may be considered, forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. The words "believe," "expect," "anticipate," "project" and similar expressions and uses of future or conditional verbs, generally identify forward-looking statements. AbbVie cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those expressed or implied in the forward-looking statements. Such risks and uncertainties include, but are not limited to, challenges to intellectual property, competition from other products, difficulties inherent in the research and development process, adverse litigation or government action, changes to laws and regulations applicable to our industry, the impact of global macroeconomic factors, such as economic downturns or uncertainty, international conflict, trade disputes and tariffs, and other uncertainties and risks associated with global business operations. Additional information about the economic, competitive, governmental, technological and other factors that may affect AbbVie's operations is set forth in Item 1A, "Risk Factors," of AbbVie's 2025 Annual Report on Form 10-K, which has been filed with the Securities and Exchange Commission, as updated by its Quarterly Reports on Form 10-Q and in other documents that AbbVie subsequently files with the Securities and Exchange Commission that update, supplement or supersede such information. AbbVie undertakes no obligation, and specifically declines, to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.

References

Braz A, Eduardo CC de P, Pierce A, et al. A Novel Hybrid Injectable for Soft-tissue Augmentation: Analysis of Data and Practical Experience. Plast Reconstr Surg Glob Open. 2024;12(9):e6190.
Humphrey S, Nikolis A, Urdiales Gálvez F, et al. Treatment of Midface Volume Deficits with a Hybrid Hyaluronic Acid and Calcium Hydroxyapatite Injectable in Participants Undergoing GLP-1 Medical Weight Loss: A Safety and Efficacy Subgroup Analysis from a Pivotal Study. To be presented at AMWC Dubai 2026; Dubai, UAE.
Humphrey S, Demosthenous N, Nikolis A, et al. Complete Analysis of a 24-Month Multicenter, Evaluator-Blinded, Randomized, Parallel-Group Study to Evaluate the Safety and Effectiveness of a Hybrid Hyaluronic Acid and Calcium Hydroxyapatite Injectable for Midface Soft Tissue Augmentation. To be presented at AMWC Dubai 2026; Dubai, UAE.
Mukherjee M, Aleisa AM, Raza A, Musumeci M. Patient-Perceived Satisfaction and Benefits of Long-Term OnabotulinumtoxinA for Upper Facial Lines: A Sub-Analysis of Patients From Middle Eastern Sites From a Global Retrospective Chart Review and Cross-Sectional Study. To be presented at AMWC Dubai 2026; Dubai, UAE. 

SOURCE AbbVie

Focused Alpha LLC increased its holdings in AbbVie Inc. (NYSE:ABBV – Free Report) by 109.0% during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 4,657 shares of the company’s stock after purchasing an additional 2,429 shares during the period. Focused Alpha LLC’s holdings in AbbVie were worth $1,218,000 at the end of the most recent quarter.

Several other institutional investors have also bought and sold shares of the business. Corient Private Wealth LP purchased a new stake in AbbVie during the second quarter valued at approximately $559,736,000. Legal & General Group Plc bought a new position in AbbVie during the 2nd quarter valued at about $2,905,952,000. Jupiter Topco LLC bought a new stake in AbbVie in the second quarter worth about $1,560,354,000. Diamant Asset Management Inc. grew its stake in shares of AbbVie by 21,649.0% during the first quarter. Diamant Asset Management Inc. now owns 3,671,231 shares of the company’s stock valued at $798,456,000 after buying an additional 3,654,351 shares during the last quarter. Finally, Canada Pension Plan Investment Board bought a new stake in shares of AbbVie during the 2nd quarter worth approximately $817,473,000. Institutional investors own 70.23% of the company’s stock.

Insider Transactions at AbbVie In other news, EVP Nicholas Donoghoe sold 32,710 shares of the company’s stock in a transaction on Friday, August 14th. The stock was sold at an average price of $250.00, for a total value of $8,177,500.00. Following the transaction, the executive vice president owned 74,430 shares of the company’s stock, valued at $18,607,500. This represents a 30.53% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. 0.06% of the stock is currently owned by company insiders.

AbbVie Trading Up 2.1% ABBV stock opened at $288.66 on Wednesday. AbbVie Inc. has a 12-month low of $190.75 and a 12-month high of $291.40. The business’s 50-day moving average is $264.22 and its 200 day moving average is $240.39. The stock has a market cap of $510.01 billion, a price-to-earnings ratio of 81.54, a PEG ratio of 1.29 and a beta of 0.24. AbbVie (NYSE:ABBV – Get Free Report) last issued its quarterly earnings results on Friday, July 31st. The company reported $3.65 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.61 by $0.04. The firm had revenue of $16.99 billion for the quarter, compared to analyst estimates of $16.80 billion. AbbVie had a negative return on equity of 422.07% and a net margin of 9.80%. The business’s revenue was up 10.2% on a year-over-year basis. During the same period in the previous year, the company posted $2.97 earnings per share. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. As a group, equities analysts forecast that AbbVie Inc. will post 13.94 EPS for the current fiscal year.

AbbVie Dividend Announcement The company also recently announced a quarterly dividend, which will be paid on Monday, November 16th. Shareholders of record on Thursday, October 15th will be issued a $1.73 dividend. This represents a $6.92 annualized dividend and a yield of 2.4%. The ex-dividend date is Thursday, October 15th. AbbVie’s payout ratio is presently 195.48%.

More AbbVie News Here are the key news stories impacting AbbVie this week:

Positive Sentiment: Promising Crohn’s disease results strengthen AbbVie’s pipeline. In a Phase 2a study, investigational ABBV-466, a dual-targeting therapy against IL-23 and integrin α4β7, produced higher endoscopic remission rates than either monotherapy at Week 12, with the treatment advantage widening by Week 24. The results suggest a potential future combination option in inflammatory bowel disease and helped reinforce AbbVie’s immunology strategy. AbbVie Presents Data for ABBV-466 Positive Sentiment: Analysts see continued growth in neuroscience. AbbVie’s neuroscience franchise is projected to deliver nearly 16% revenue growth in the third quarter, supported by established products and newer Parkinson’s disease therapies. This offers another source of expansion as the company manages the loss of exclusivity for Humira. AbbVie’s Neuroscience Franchise Positive Sentiment: Strong cash generation supports the investment case. A comparison with Vertex highlighted AbbVie’s substantial free cash flow and its ability to navigate Humira’s patent expiration, factors that may support dividends, business development and pipeline investment. AbbVie vs. Vertex Pharmaceuticals Neutral Sentiment: McLaren Formula 1 partnership raises AbbVie’s visibility. The multiyear sponsorship and “Race to Innovate” campaign will promote awareness of immune-mediated diseases and provide charitable donations tied to McLaren’s championship points. The initiative is strategically positive for brand recognition but is unlikely to materially affect near-term earnings. AbbVie Named Official Pharmaceutical Partner of McLaren Negative Sentiment: Competitive risk remains in immunology. Reports that Rapport Therapeutics may enter a market estimated at $4.3 billion—and positive commentary surrounding Spyre Therapeutics’ ulcerative-colitis combination approach—highlight potential future competition. However, these programs remain developmental and do not appear to change AbbVie’s near-term results. Rapport Enters AbbVie Market Analyst Upgrades and Downgrades A number of research firms have recently commented on ABBV. Barclays upped their price target on shares of AbbVie from $275.00 to $300.00 and gave the stock an “overweight” rating in a report on Wednesday, July 29th. Rothschild & Co Redburn increased their target price on AbbVie from $284.00 to $285.00 and gave the company a “buy” rating in a research report on Tuesday, August 4th. Scotiabank boosted their price objective on shares of AbbVie from $280.00 to $320.00 and gave the stock an “outperform” rating in a research note on Tuesday, October 6th. Oppenheimer boosted their target price on AbbVie from $244.00 to $258.00 and gave the stock a “neutral” rating in a research note on Monday, August 3rd. Finally, Wells Fargo & Company increased their price objective on shares of AbbVie from $295.00 to $300.00 and gave the company an “overweight” rating in a research report on Monday, August 17th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating and six have issued a Hold rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $277.18.

View Our Latest Stock Report on AbbVie

AbbVie Company Profile (Free Report)

AbbVie Inc (NYSE: ABBV) is a global biopharmaceutical company that discovers, develops and commercializes medicines and other healthcare products. Its portfolio focuses on immunology, oncology, neuroscience, aesthetics and eye care, serving patients and healthcare providers in markets around the world.

The company’s key products include immunology medicines such as Skyrizi and Rinvoq; neuroscience treatments including Vraylar, Ubrelvy and Qulipta; and oncology products such as Imbruvica and Venclexta.

Featured Stories Five stocks we like better than AbbVie Aurora Rejects Curaleaf’s Higher Bid, But the Takeover Fight Isn’t Over Centrus Energy Is Building a Nuclear Fuel Powerhouse—Why Is Its Stock Struggling? Halliburton Gains Traction: Multiyear Upcycle Ahead Meta Platforms’ AI Comeback Faces an Earnings Test—And a $10 Billion Charge Want to see what other hedge funds are holding ABBV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AbbVie Inc. (NYSE:ABBV – Free Report).

Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with MarketBeat.com's FREE daily email newsletter.

Greg Jennings LLC acquired a new stake in shares of AbbVie Inc. (NYSE: ABBV) during the undefined quarter, according to its most recent 13F filing with the SEC. The firm acquired 27,954 shares of the company's stock, valued at approximately $7,313,000. AbbVie makes up 4.9% of Greg Jennings LLC's portfolio, making the stock

Multi-year, purpose-driven campaign connects McLaren's on-track performance with support for global patient advocacy organizations serving people living with immune-mediated diseases Through the partnership, AbbVie will donate $10,000 to global charities for every 10 Constructors' Championship points earned by McLaren, reflecting approximately 10% of people worldwide affected by autoimmune diseases1,2 AbbVie Race to Innovate will launch at the 2026 Formula 1 United States Grand Prix in Austin and expand throughout the 2027 season , /PRNewswire/ -- AbbVie (NYSE: ABBV), a global pharmaceutical leader, and McLaren Racing today announced a multi-year partnership naming AbbVie an Official Pharmaceutical Partner of the McLaren Mastercard Formula 1 Team. At the center of the partnership is AbbVie Race to Innovate, a multi-year, purpose-driven campaign, built on a shared belief that innovation is never finished.

Race to Innovate turns McLaren's on-track performance into meaningful impact. AbbVie will donate $10,000 to global charities for every 10 Constructors' Championship points earned by McLaren, reflecting approximately 10% of the global population impacted by autoimmune diseases.1,2 Donations will support global patient advocacy organizations that provide education, resources and support for people living with immune-mediated diseases.

Across medicine and motorsport, progress depends on a relentless pursuit of innovation, expert teams working together to solve complex challenges and the precision and data needed to continually learn, refine and improve outcomes. Race to Innovate will bring that shared approach to life through storytelling that showcase the people, teams and thinking behind progress in both fields.

"AbbVie and McLaren may operate in different industries, but both are driven by a mindset of continuous improvement and shared determination to solve complex challenges," said Tracie Haas, senior vice president, corporate affairs, AbbVie. "As a leader in immunology for nearly three decades, AbbVie is pressing forward to drive innovation for patients. Through Race to Innovate, we're proud to bring that commitment to a global stage with McLaren, turning every 10 points scored on the track into support for people living with immune-mediated diseases and the organizations that serve them."

Race to Innovate will launch at the 2026 Formula 1 United States Grand Prix in Austin, marking the start of AbbVie's partnership with the McLaren Mastercard Formula 1 Team. The global attention surrounding the race weekend provides a powerful moment to introduce the partnership, raise awareness of immune-mediated diseases and connect the excitement of Formula 1 with meaningful support for communities around the world. The launch builds on AbbVie's commitment to advancing the standard of care for people living with immune-mediated diseases, using the global reach of Formula 1 to bring greater visibility to new audiences.

"We're proud to welcome AbbVie to McLaren Racing at such an exciting moment for our team, ahead of the United States Grand Prix," said Matt Dennington, Co-Chief Commercial Officer, McLaren Racing. "This partnership brings together two organizations that share a relentless pursuit of progress, whether that's pushing the limits of performance on track or advancing life-changing science off it. We're looking forward to working with AbbVie to tell powerful stories about what it takes to drive progress, and to showcase the people and ideas behind it."

In 2027, Race to Innovate will build on its inaugural launch throughout the full Formula 1 season. As part of its ongoing commitment to support the immune-mediated disease community, AbbVie will continue donating for the full season while storytelling and fan engagement efforts will further highlight the shared pursuit of progress at the heart of the partnership.

For more information about Race to Innovate and AbbVie's purpose-driven partnership with McLaren Mastercard F1 Team, visit abbvie.com/mclarenf1.

Sources

Conrad N, Misra S, Verbakel JY, et al. Incidence, prevalence, and co-occurrence of autoimmune disorders over time and by age, sex, and socioeconomic status: a population-based cohort study of 22 million individuals in the UK. Lancet. 2023;401(10391):1878-1890. Xiao, XP., Wu, MY, Li, Y, et al. Global landscape of autoimmune diseases across different lifespan: A three-decade perspective. Medicine. 2026;105(2):1-17. About AbbVie
AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas including immunology, neuroscience and oncology – and products and services in our Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on LinkedIn, Facebook, Instagram, X and YouTube.

About AbbVie in Immunology
AbbVie is relentless in our pursuit to redefine the standard of care for patients living with immune-mediated conditions, with the goal of helping them live a life free from the limitations of their disease. For nearly 30 years, AbbVie has led and helped shape the field of immunology through groundbreaking science and trusted medicines. Building on deep expertise across gastroenterology, rheumatology and dermatology, and other areas of high unmet need, we continue to invest in a broad and differentiated pipeline – spanning innovative modalities, novel mechanisms of action and next-generation approaches designed to conquer the complex biology underlying immune-mediated disease.

Today, more than 1 million patients worldwide are treated with AbbVie's immunology medicines, approved in more than 175 countries across 20+ immune-mediated diseases that impact adult and pediatric populations. As we work to strengthen our legacy and drive the next wave of innovation, we remain focused on delivering meaningful progress for patients and expanding access to our medicines. For more information, please visit www.abbvie.com/immunology.

About McLaren Racing
McLaren Racing was founded by racing driver Bruce McLaren in 1963. The team entered its first Formula 1 race in 1966. McLaren has since won 23 Formula 1 world championships, over 200 Formula 1 Grands Prix, the Indianapolis 500 three times, and the Le Mans 24 Hours at its first attempt.

McLaren Racing competes across three racing series. The team competes in the FIA Formula 1 World Championship with McLaren Mastercard F1 drivers Lando Norris and Oscar Piastri, the NTT INDYCAR SERIES with Arrow McLaren drivers Pato O'Ward, Nolan Siegel and Christian Lundgaard, and F1 Academy with Driver Development Programme members Ella Lloyd and Ella Stevens.

McLaren is a champion for sustainability in the sport and a signatory to the UN Sports for Climate Action Commitment. It is committed to achieving net zero by 2040 and fostering a diverse and inclusive culture in the motorsport industry.

McLaren Racing – Official Website

Forward-Looking Statements
Some statements in this news release are, or may be considered, forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. The words "believe," "expect," "anticipate," "project" and similar expressions and uses of future or conditional verbs, generally identify forward-looking statements. AbbVie cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those expressed or implied in the forward-looking statements. Such risks and uncertainties include, but are not limited to, challenges to intellectual property, competition from other products, difficulties inherent in the research and development process, adverse litigation or government action, changes to laws and regulations applicable to our industry, the impact of global macroeconomic factors, such as economic downturns or uncertainty, international conflict, trade disputes and tariffs, and other uncertainties and risks associated with global business operations. Additional information about the economic, competitive, governmental, technological and other factors that may affect AbbVie's operations is set forth in Item 1A, "Risk Factors," of AbbVie's 2025 Annual Report on Form 10-K, which has been filed with the Securities and Exchange Commission, as updated by its Quarterly Reports on Form 10-Q and in other documents that AbbVie subsequently files with the Securities and Exchange Commission that update, supplement or supersede such information. AbbVie undertakes no obligation, and specifically declines, to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.

SOURCE AbbVie

Key Takeaways AbbVie's neuroscience revenues are expected to grow roughly 16% to $3.29 billion in Q3 2026.Vraylar sales are projected at $1.08 billion, while Botox Therapeutic sales are expected to be 1.07 billion.Vyalev sales are expected to reach $283 million, while Juvmo's launch could draw investor attention. Although immunology remains AbbVie’s (ABBV - Free Report) largest revenue-generating franchise, neuroscience is emerging as another important growth driver. Spanning psychiatry, migraine and Parkinson’s disease (PD), the franchise offers multiple avenues for expansion through established treatments and newer products. Investors will be keen to know how the segment performed in the third quarter when the company announces results on Oct. 30.

The Zacks Consensus Estimate for AbbVie’s neuroscience revenues in the third quarter of 2026 is pegged at $3.29 billion. The figure implies year-over-year growth of nearly 16%, with growth expected across most marketed products.

A Closer Look at ABBV’s Neuroscience DrugsAbbVie’s established brands, Vraylar and Botox Therapeutic, are expected to remain significant contributors to neuroscience revenues. Vraylar is used to treat several psychiatric conditions, while Botox Therapeutic has multiple approved uses, including chronic migraine prevention, spasticity and cervical dystonia. The Zacks Consensus Estimate for Vraylar sales is pegged at $1.08 billion, while the same for Botox stands at $1.07 billion.

Turning to the oral migraine portfolio, the Zacks Consensus Estimate for Ubrelvy sales is pinned at $393 million, while that for Qulipta is pegged at $364 million. Ubrelvy is used for the acute treatment of migraine attacks, whereas Qulipta is indicated for migraine prevention.

Among the newer products, Vyalev is projected to generate $283 million in revenues, up from $256 million generated in the previous quarter. AbbVie expects the PD therapy to achieve blockbuster status in 2026 as domestic uptake accelerates.

Meanwhile, AbbVie received FDA approval for Juvmo, a once-daily oral treatment for PD, in late September. Given the timing of the approval — just days before the end of the third quarter — the drug is unlikely to make a meaningful contribution to revenues during the period. Investors will likely look for management commentary on the initial launch and early uptake.

Other Players in the Neuroscience SpaceAbbVie faces competition from large-cap biotech/pharmaceutical companies in the market, which include Biogen (BIIB - Free Report) and Johnson & Johnson (JNJ - Free Report) .

As revenues from its legacy multiple sclerosis portfolio continue to decline, Biogen is increasingly focused on expanding its neuroscience business through newer therapies. Along with partner Eisai, Biogen markets Leqembi, one of the two FDA-approved treatments for AD. The company also markets Zurzuvae, the first FDA-approved oral treatment for postpartum depression.

J&J's neuroscience business is anchored by the blockbuster depression therapy Spravato and long-acting antipsychotic Invega Sustenna. The company's acquisition of Intra-Cellular Therapies last year further strengthened its portfolio by adding Caplyta, an approved treatment for schizophrenia and bipolar depression.

IFP Advisors Inc boosted its position in AbbVie Inc. (NYSE:ABBV – Free Report) by 3.7% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 54,869 shares of the company’s stock after buying an additional 1,939 shares during the period. IFP Advisors Inc’s holdings in AbbVie were worth $14,353,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also bought and sold shares of ABBV. Burk Holdings LLC acquired a new stake in AbbVie during the 2nd quarter worth about $30,000. Merkkuri Wealth Advisors LLC acquired a new position in shares of AbbVie in the 1st quarter valued at about $34,000. Marquette Asset Management LLC lifted its stake in shares of AbbVie by 52.2% in the 2nd quarter. Marquette Asset Management LLC now owns 140 shares of the company’s stock valued at $35,000 after purchasing an additional 48 shares during the period. IMG Wealth Management Inc. lifted its stake in shares of AbbVie by 3,060.0% in the 2nd quarter. IMG Wealth Management Inc. now owns 158 shares of the company’s stock valued at $40,000 after purchasing an additional 153 shares during the period. Finally, Principia Wealth Advisory LLC lifted its stake in shares of AbbVie by 38.9% in the 2nd quarter. Principia Wealth Advisory LLC now owns 157 shares of the company’s stock valued at $40,000 after purchasing an additional 44 shares during the period. Institutional investors and hedge funds own 70.23% of the company’s stock.

Wall Street Analysts Forecast Growth
ABBV has been the topic of several research analyst reports. Argus upped their target price on AbbVie from $250.00 to $270.00 in a research report on Tuesday, August 4th. Cantor Fitzgerald boosted their price target on AbbVie from $285.00 to $290.00 and gave the company an “overweight” rating in a research note on Thursday, October 8th. Citigroup boosted their price target on AbbVie from $230.00 to $260.00 and gave the company a “neutral” rating in a research note on Wednesday, July 15th. Morgan Stanley increased their price target on AbbVie from $296.00 to $310.00 and gave the stock an “overweight” rating in a report on Wednesday, October 7th. Finally, Rothschild & Co Redburn raised their price objective on shares of AbbVie from $284.00 to $285.00 and gave the stock a “buy” rating in a research report on Tuesday, August 4th. One investment analyst has rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating and six have issued a Hold rating to the stock. According to data from MarketBeat, AbbVie has a consensus rating of “Moderate Buy” and an average price target of $277.18.

View Our Latest Stock Analysis on AbbVie
Trending Headlines about AbbVie
Here are the key news stories impacting AbbVie this week:

Positive Sentiment: Positive Phase 3 cancer-trial results provided the most important company-specific catalyst. AbbVie and Genmab reported that epcoritamab plus R-CHOP significantly reduced the risk of disease progression or death in newly diagnosed diffuse large B-cell lymphoma, strengthening AbbVie’s oncology pipeline and potential long-term growth. What Does AbbVie (ABBV) 51% DLBCL Risk Reduction Mean For Its Oncology Push?
Positive Sentiment: Analyst and options-market confidence remains favorable. Erste Group Bank issued a positive earnings outlook, Royal Bank of Canada reaffirmed its Outperform rating, and traders purchased an unusually high volume of ABBV call options—signals of bullish expectations ahead of results. Erste Group Bank Issues Positive Outlook for AbbVie Earnings
Positive Sentiment: Investors continue to view AbbVie as attractively valued for a large-cap pharmaceutical company. Coverage highlights a forward P/E near 16.4, strong year-to-date performance, a durable dividend, and newer medicines growing fast enough to offset declining Humira revenue. AbbVie is Outperforming the Market this Year So Far. Is Its 16.4x Valuation Attractive?
Positive Sentiment: Sector rotation is helping the stock. Investors have been shifting toward defensive pharmaceutical companies as technology stocks weaken, pushing major drugmakers close to record highs. Big Pharma Stocks Close Near All-Time Highs
Neutral Sentiment: Investors are now looking ahead to AbbVie’s third-quarter earnings report, scheduled for October 30. The results and updated guidance will test whether recent pipeline momentum and newer-drug growth justify the stock’s rally. AbbVie’s Q3 2026 Earnings: What to Expect
Negative Sentiment: The primary risk remains the transition away from established blockbusters. AbbVie must prove that newer medicines can sustain earnings as mature products face competition, while its trailing valuation appears elevated despite a more reasonable forward multiple. AbbVie vs. Merck: Which Pharma Stock Offers Better Value?

Insider Transactions at AbbVie
In other AbbVie news, EVP Nicholas Donoghoe sold 32,710 shares of the business’s stock in a transaction on Friday, August 14th. The shares were sold at an average price of $250.00, for a total transaction of $8,177,500.00. Following the completion of the sale, the executive vice president owned 74,430 shares in the company, valued at approximately $18,607,500. The trade was a 30.53% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Insiders own 0.06% of the company’s stock.

AbbVie Stock Performance
Shares of AbbVie stock opened at $285.32 on Monday. AbbVie Inc. has a 52 week low of $190.75 and a 52 week high of $291.40. The stock has a 50 day moving average price of $262.74 and a two-hundred day moving average price of $239.41. The stock has a market capitalization of $504.10 billion, a PE ratio of 80.60, a price-to-earnings-growth ratio of 1.30 and a beta of 0.24.

AbbVie (NYSE:ABBV – Get Free Report) last released its quarterly earnings data on Friday, July 31st. The company reported $3.65 EPS for the quarter, beating the consensus estimate of $3.61 by $0.04. AbbVie had a negative return on equity of 422.07% and a net margin of 9.80%. The firm had revenue of $16.99 billion during the quarter, compared to the consensus estimate of $16.80 billion. During the same quarter in the previous year, the company posted $2.97 earnings per share. The company’s quarterly revenue was up 10.2% on a year-over-year basis. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. Research analysts forecast that AbbVie Inc. will post 13.94 EPS for the current year.

AbbVie Announces Dividend
The firm also recently declared a quarterly dividend, which will be paid on Monday, November 16th. Investors of record on Thursday, October 15th will be given a $1.73 dividend. The ex-dividend date of this dividend is Thursday, October 15th. This represents a $6.92 annualized dividend and a yield of 2.4%. AbbVie’s dividend payout ratio (DPR) is presently 195.48%.

About AbbVie
(Free Report)

AbbVie Inc (NYSE: ABBV) is a global biopharmaceutical company that discovers, develops and commercializes medicines and other healthcare products. Its portfolio focuses on immunology, oncology, neuroscience, aesthetics and eye care, serving patients and healthcare providers in markets around the world.

The company’s key products include immunology medicines such as Skyrizi and Rinvoq; neuroscience treatments including Vraylar, Ubrelvy and Qulipta; and oncology products such as Imbruvica and Venclexta.

Featured Articles

Five stocks we like better than AbbVie
These 3 Green Stocks Have a Growth Story That Goes Far Beyond Washington
Meta Claims Frontier-Class AI Status With New Muse Wonder Models
Berkshire Just Backed This Little-Known Stock—Should You Chase It?
Broadcom’s CEO Sees Years of AI Demand But Warns of a Bigger Threat to the Boom

Want to see what other hedge funds are holding ABBV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AbbVie Inc. (NYSE:ABBV – Free Report).

Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with MarketBeat.com's FREE daily email newsletter.

Banque Pictet & Cie SA cut its stake in AbbVie Inc. (NYSE:ABBV – Free Report) by 8.3% in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 375,536 shares of the company’s stock after selling 33,788 shares during the period. AbbVie accounts for about 0.7% of Banque Pictet & Cie SA’s portfolio, making the stock its 24th largest position. Banque Pictet & Cie SA’s holdings in AbbVie were worth $98,236,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors also recently bought and sold shares of the stock. James T. Borello RIA lifted its position in AbbVie by 3.5% during the 3rd quarter. James T. Borello RIA now owns 1,192 shares of the company’s stock worth $312,000 after acquiring an additional 40 shares during the period. ACT Advisors LLC. increased its holdings in AbbVie by 2.5% in the 2nd quarter. ACT Advisors LLC. now owns 1,688 shares of the company’s stock worth $425,000 after buying an additional 41 shares during the period. Willner & Heller LLC raised its position in AbbVie by 0.7% during the 2nd quarter. Willner & Heller LLC now owns 5,852 shares of the company’s stock worth $1,472,000 after buying an additional 43 shares during the last quarter. B.O.S.S. Retirement Advisors LLC raised its position in AbbVie by 3.1% during the 2nd quarter. B.O.S.S. Retirement Advisors LLC now owns 1,427 shares of the company’s stock worth $359,000 after buying an additional 43 shares during the last quarter. Finally, Fielder Capital Group LLC raised its position in AbbVie by 1.7% during the 2nd quarter. Fielder Capital Group LLC now owns 2,532 shares of the company’s stock worth $637,000 after buying an additional 43 shares during the last quarter. 70.23% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets Several analysts have recently commented on the stock. BNP Paribas Exane upped their price objective on shares of AbbVie from $218.00 to $247.00 and gave the company a “neutral” rating in a report on Tuesday, August 11th. Oppenheimer boosted their price target on AbbVie from $244.00 to $258.00 and gave the company a “neutral” rating in a report on Monday, August 3rd. Bank of America restated a “buy” rating on shares of AbbVie in a research report on Tuesday, September 8th. Weiss Ratings raised shares of AbbVie from a “buy (b-)” rating to a “buy (b)” rating in a research note on Thursday, October 8th. Finally, JPMorgan Chase & Co. raised their price objective on shares of AbbVie from $285.00 to $300.00 and gave the stock an “overweight” rating in a research note on Thursday, October 8th. One research analyst has rated the stock with a Strong Buy rating, twenty-three have given a Buy rating and six have issued a Hold rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $277.18.

View Our Latest Analysis on ABBV AbbVie Price Performance ABBV stock opened at $285.32 on Friday. The business has a 50 day simple moving average of $262.74 and a 200-day simple moving average of $239.22. The firm has a market capitalization of $504.10 billion, a PE ratio of 80.60, a price-to-earnings-growth ratio of 1.29 and a beta of 0.24. AbbVie Inc. has a 1 year low of $190.75 and a 1 year high of $291.40.

AbbVie (NYSE:ABBV – Get Free Report) last announced its quarterly earnings data on Friday, July 31st. The company reported $3.65 EPS for the quarter, topping analysts’ consensus estimates of $3.61 by $0.04. The firm had revenue of $16.99 billion for the quarter, compared to the consensus estimate of $16.80 billion. AbbVie had a negative return on equity of 422.07% and a net margin of 9.80%. The firm’s revenue was up 10.2% compared to the same quarter last year. During the same quarter last year, the business posted $2.97 earnings per share. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. On average, equities research analysts expect that AbbVie Inc. will post 13.94 EPS for the current year.

AbbVie Announces Dividend The company also recently announced a quarterly dividend, which will be paid on Monday, November 16th. Shareholders of record on Thursday, October 15th will be paid a dividend of $1.73 per share. The ex-dividend date of this dividend is Thursday, October 15th. This represents a $6.92 dividend on an annualized basis and a yield of 2.4%. AbbVie’s payout ratio is 195.48%.

More AbbVie News Here are the key news stories impacting AbbVie this week:

Positive Sentiment: Positive Phase 3 cancer-trial results provided the most important company-specific catalyst. AbbVie and Genmab reported that epcoritamab plus R-CHOP significantly reduced the risk of disease progression or death in newly diagnosed diffuse large B-cell lymphoma, strengthening AbbVie’s oncology pipeline and potential long-term growth. What Does AbbVie (ABBV) 51% DLBCL Risk Reduction Mean For Its Oncology Push? Positive Sentiment: Analyst and options-market confidence remains favorable. Erste Group Bank issued a positive earnings outlook, Royal Bank of Canada reaffirmed its Outperform rating, and traders purchased an unusually high volume of ABBV call options—signals of bullish expectations ahead of results. Erste Group Bank Issues Positive Outlook for AbbVie Earnings Positive Sentiment: Investors continue to view AbbVie as attractively valued for a large-cap pharmaceutical company. Coverage highlights a forward P/E near 16.4, strong year-to-date performance, a durable dividend, and newer medicines growing fast enough to offset declining Humira revenue. AbbVie is Outperforming the Market this Year So Far. Is Its 16.4x Valuation Attractive? Positive Sentiment: Sector rotation is helping the stock. Investors have been shifting toward defensive pharmaceutical companies as technology stocks weaken, pushing major drugmakers close to record highs. Big Pharma Stocks Close Near All-Time Highs Neutral Sentiment: Investors are now looking ahead to AbbVie’s third-quarter earnings report, scheduled for October 30. The results and updated guidance will test whether recent pipeline momentum and newer-drug growth justify the stock’s rally. AbbVie’s Q3 2026 Earnings: What to Expect Negative Sentiment: The primary risk remains the transition away from established blockbusters. AbbVie must prove that newer medicines can sustain earnings as mature products face competition, while its trailing valuation appears elevated despite a more reasonable forward multiple. AbbVie vs. Merck: Which Pharma Stock Offers Better Value? Insiders Place Their Bets In other AbbVie news, EVP Nicholas Donoghoe sold 32,710 shares of the business’s stock in a transaction dated Friday, August 14th. The shares were sold at an average price of $250.00, for a total value of $8,177,500.00. Following the transaction, the executive vice president directly owned 74,430 shares in the company, valued at $18,607,500. The trade was a 30.53% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. 0.06% of the stock is owned by insiders.

AbbVie Profile (Free Report)

AbbVie Inc is a global biopharmaceutical company that develops, manufactures and markets medicines for a range of serious and chronic health conditions. Its portfolio spans immunology, oncology, neuroscience, eye care, aesthetics, gastroenterology and women’s health.

The company’s products include the immunology medicines Skyrizi and Rinvoq; neuroscience treatments such as Vraylar, Ubrelvy and Qulipta; and oncology medicines including Imbruvica and Venclexta. AbbVie also markets Botox Cosmetic and Botox Therapeutic, as well as other products for aesthetics, eye care and specialty care.

AbbVie was established in 2013 as an independent, publicly traded company following its separation from Abbott Laboratories.

See Also Five stocks we like better than AbbVie Bank of America Stock Sell-Off Looks Like a Buying Opportunity AST SpaceMobile Is Down 67%—Could SpaceX’s Mobile Push Deepen the Selloff? GlobalFoundries’ $21 Billion Deal Could Change the Economics of Chipmaking Fundamental and Technicals Signals Align for Costco: Is the Stock Finally Breaking Out? Want to see what other hedge funds are holding ABBV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AbbVie Inc. (NYSE:ABBV – Free Report).

Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with MarketBeat.com's FREE daily email newsletter.

20 scientific presentations underscore the breadth of AbbVie's leadership in Inflammatory Bowel Disease (IBD) research programsLatest long-term and real-world data with SKYRIZI®(risankizumab) and RINVOQ® (upadacitinib) provide additional insight into clinical and endoscopic outcomes over approximately three years in moderately to severely active Crohn's disease and ulcerative colitisNew data evaluating endoscopic remission with investigational dual-targeting therapy ABBV-466 in patients with moderate-to-severe Crohn's disease will also be presented, /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced the presentation of 20 new scientific abstracts from its IBD portfolio at the 2026 United European Gastroenterology (UEG) Week, October 17-20 in Barcelona, Spain. Together, the data reflect the breadth of AbbVie's research across IBD, including established therapies studied over longer treatment periods and in real-world clinical practice.

"Crohn's disease and ulcerative colitis are chronic, lifelong conditions, and understanding how patients respond to treatment over time and in everyday clinical practice is critical," said Sofie Berg, Pharm.D., Ph.D., therapeutic area head, immunology, international medical affairs, AbbVie. "The data presented at UEGW 2026 build on our growing body of evidence that can help clinicians move toward favorable long-term outcomes for people living with IBD."

Key data to be presented include:

Long-term data in moderately to severely active ulcerative colitis (UC) and Crohn's disease (CD) – Open-label extension and post-hoc analyses add to the evidence base for clinical and endoscopic outcomes with risankizumab and upadacitinib

Risankizumab in UC: COMMAND showed sustained clinical and endoscopic outcomes up to three years of maintenance treatment. As-observed clinical remissiona rates of 54.0%–73.1% and endoscopic remissionb rates of 38.8%–53.5% were achieved at week 96 with 180mg across advanced therapy-naïve and advanced therapy-experienced patients.Upadacitinib in CD: U-ENDURE as-observed analyses showed that clinical and endoscopic outcomes were maintained through approximately four years of treatment. At Week 144, clinical remissionc was achieved by 78.9% of patients receiving 15 mg and 86.6% receiving 30 mg. Endoscopic remissiond was achieved by 47.1% and 64.2% of patients, respectively.Upadacitinib in the Real World: New Insights from Clinical Practice

Interim results from the real-world UPlift study showed that 70.2% of evaluable patients (N=497) with moderate to severe Crohn's disease achieved clinical responsee with upadacitinib within 12 weeks, with a median time to first response of 13 days.A real-world claims analysis of patients (N=514) with UC or CD showed that patients who switched from a Tumor Necrosis Factor inhibitor (TNFi) to upadacitinib had lower rates of IBD-related hospitalizations (9.5% vs 16.3%) or surgery (6.9% vs 10.6%) over 12 months compared with patients who cycled to another TNFi.Additional Findings on Risankizumab Subcutaneous Induction in CD

Data presented at UEGW will further expand on findings from the Phase 3 AFFIRM study evaluating subcutaneous risankizumab induction and maintenance in CD. Following the first presentation of AFFIRM results at the 2026 American College of Gastroenterology Annual Scientific Meeting, the UEGW presentations will provide additional analyses examining outcomes by prior advanced therapy exposure and further characterizing clinical and endoscopic outcomes among patients who responded to subcutaneous risankizumab induction and continued treatment.aDefined as stool frequency (SF) score ≤ 1, and not greater than baseline, rectal bleeding score = 0, and endoscopic subscore ≤ 1 without evidence of friability.
bDefined as endoscopic subscore = 0.
cDefined as average daily very soft or liquid SF ≤2.8 and average daily abdominal pain (AP) score ≤1.0 and both not greater than induction baseline.
dDefined as Simplified Endoscopic Score for Patients with Crohn's Disease ≤ 4 and at least a 2-point reduction from baseline and no subscore > 1 in any individual variable, as scored by a central reviewer.
eDefined as the first day with ≥30% decrease in daily very soft or liquid SF and/or ≥30% decrease in daily AP score and both not worse than baseline AND a prospective 7-day average daily CR-PRO starting on the first day of daily CR-PRO; prospective 7-day average daily CR-PRO was defined as ≥30% decrease in average daily very soft or liquid SF and/or ≥30% decrease in average daily AP score and both not worse than baseline. Only patients with either baseline SF or AP >0 and both non-missing with at least one postbaseline assessment of CR-PRO2 are included.

The 2026 UEGW Congress program is available here. Select abstracts and oral presentations from AbbVie include:

Presentation Title

Session Details

Efficacy of Risankizumab by Crohn's Disease
Location: Results From 144 Weeks of the
FORTIFY Open-Label Extension Study

Oral

Monday, 19 October

16:00 – 17:00

OP165: Teaching an old dog new tricks:
New implementations of current IBD drug

Efficacy and Safety of Risankizumab
Subcutaneous Induction in Patients With
Moderately to Severely Active Crohn's Disease:
Week 12 Results From the Phase 3 AFFIRM Study

Oral

Monday, 19 October

16:00 – 17:00

OP166: Teaching an old dog new tricks:
New implementations of current IBD drug

Efficacy and Safety of Subcutaneous
Risankizumab Maintenance Therapy Among
Patients With Moderately to Severely Active
Crohn's Disease Who Responded to
Subcutaneous Risankizumab Induction Therapy:
24-Week Results From the AFFIRM Trial

Moderated poster

Monday, 19 October

16:00 – 17:00

MP0087: The IBD exposome: Diet,
environment, and sustainability

Sustained Clinical and Endoscopic Improvements With
up to 3 Years of Risankizumab Maintenance
Treatment in Patients with Moderate to Severe
Ulcerative Colitis Regardless of the Number of Prior
Advanced Therapy Exposures

E-Poster

17-20 October

PP1176

Efficacy and Safety of Upadacitinib Maintenance
Therapy in Moderately to Severely Active
Crohn's Disease: 144-Week Results From the U-
ENDURE Long-Term Extension Study

Oral

Monday, 19 October

11:30 – 12:30

OP108: Long term outcomes
of interventional trials in IBD

Effectiveness of Upadacitinib Treatment in
Moderate to Severe Crohn's Disease in Real-
World Clinical Practice: 6-Month Results From
the UPlift Study

Moderated poster

Sunday, 18 October

09:00 – 10:00

MP0015: Therapeutics in IBD - Real
world experience (3)

Comparative Health Care Resource Use and
Treatment Patterns Following Tumor Necrosis
Factor Inhibitor Cycling Versus Switching to
Upadacitinib: A Propensity Score Matched
Analysis

Oral

Tuesday, 20 October

14:30 – 15:30

OP292: Real world observations in IBD:
Things we don't see in clinical trials

ABBV-466, A Novel Dual-targeting Therapy,
Leads to Endoscopic Remission in Moderate-to-
severe Crohn's Disease: Primary Results and

Molecular Profiling from the Phase 2a TARGET-
CD study

Oral

Monday, 19 October

10:00 – 11:00

LB08: Late-Breaking IBD Trials

SKYRIZI® (risankizumab) is part of a collaboration between Boehringer Ingelheim and AbbVie, with AbbVie leading development and commercialization globally.

About SKYRIZI®
SKYRIZI is an interleukin (IL)-23 inhibitor that selectively blocks IL-23 by binding to its p19 subunit. IL-23, a cytokine involved in inflammatory processes, is thought to be linked to a number of chronic immune-mediated diseases.1 SKYRIZI is approved by the U.S. Food and Drug Administration and the European Medicines Agency for the treatment of moderately to severely active plaque psoriasis, psoriatic arthritis, Crohn's disease and ulcerative colitis.1,2

On August 27, 2026, AbbVie announced submission of an application to the European Medicines Agency (EMA) seeking approval of SKYRIZI® for subcutaneous induction for the treatment of adult patients with moderately to severely active CD.

EU Indications and Important Safety Information about SKYRIZI® (risankizumab)1

Indications

Skyrizi (risankizumab) is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy.

Skyrizi is indicated for the treatment of moderate to severe plaque psoriasis in children and adolescents from the age of 6 years who are candidates for systemic therapy.

Skyrizi, alone or in combination with methotrexate (MTX), is indicated for the treatment of active psoriatic arthritis in adults who have had an inadequate response or who have been intolerant to one or more disease-modifying antirheumatic drugs (DMARDs).

Skyrizi is indicated for the treatment of adult patients with moderately to severely active Crohn's disease who have had an inadequate response to, lost response to, or were intolerant to conventional therapy or a biologic therapy.

Skyrizi is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response to, lost response to, or were intolerant to conventional therapy or a biologic therapy.

Important Safety Information

Risankizumab is contraindicated in patients hypersensitive to the active substance or to any of the excipients, and in patients with clinically important active infections (e.g. active tuberculosis).

Risankizumab may increase the risk of infection. In patients with a chronic infection, a history of recurrent infection, or known risk factors for infection, risankizumab should be used with caution. Treatment with risankizumab should not be initiated in patients with any clinically important active infection until the infection resolves or is adequately treated.

Patients treated with risankizumab should be instructed to seek medical advice if signs or symptoms of clinically important chronic or acute infection occur. If a patient develops such an infection or is not responding to standard therapy for the infection, the patient should be closely monitored and risankizumab should not be administered until the infection resolves.

Prior to initiating treatment with risankizumab, patients should be evaluated for tuberculosis (TB) infection. Patients receiving risankizumab should be monitored for signs and symptoms of active TB. Anti-TB therapy should be considered prior to initiating risankizumab in patients with a past history of latent or active TB in whom an adequate course of treatment cannot be confirmed.

Prior to initiating therapy with risankizumab, completion of all appropriate immunizations should be considered according to current immunization guidelines. If a patient has received live vaccination (viral or bacterial), it is recommended to wait at least 4 weeks prior to starting treatment with risankizumab. Patients treated with risankizumab should not receive live vaccines during treatment and for at least 21 weeks after treatment.

Serious hypersensitivity reactions, including anaphylaxis, have been reported with use of risankizumab. If a serious hypersensitivity reaction occurs, administration of risankizumab should be discontinued immediately and appropriate therapy initiated.

The most frequently reported adverse reactions were upper respiratory infections (13% in psoriasis, 15.6% in Crohn's disease and 26.2% in ulcerative colitis).

Commonly (≥ 1/100 to

This is not a complete summary of all safety information.

See Skyrizi full Summary of Product Characteristics (SmPC) at http://www.ema.europa.eu

Globally, prescribing information varies; refer to the individual country product label for complete information.

About RINVOQ® (upadacitinib)
Discovered and developed by AbbVie scientists, RINVOQ is a selective and reversible JAK inhibitor that is being studied in several immune-mediated inflammatory diseases.3,4 In human cellular assays, RINVOQ preferentially inhibits signaling by JAK1 or JAK1/3 with functional selectivity over cytokine receptors that signal via pairs of JAK2.3

Upadacitinib (RINVOQ) is being studied in Phase 3 clinical trials for hidradenitis suppurativa, Takayasu arteritis and systemic lupus erythematosus and in pediatric studies for systemic juvenile idiopathic arthritis, atopic dermatitis, ulcerative colitis and Crohn's disease.

EU Indications and Important Safety Information about RINVOQ® (upadacitinib)3

Indications

Rheumatoid arthritis
RINVOQ is indicated for the treatment of moderate to severe active rheumatoid arthritis (RA) in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs (DMARDs). RINVOQ may be used as monotherapy or in combination with methotrexate.

Psoriatic arthritis
RINVOQ is indicated for the treatment of active psoriatic arthritis (PsA) in adult patients who have responded inadequately to, or who are intolerant to one or more DMARDs. RINVOQ may be used as monotherapy or in combination with methotrexate.

Polyarticular juvenile idiopathic arthritis
RINVOQ is indicated for the treatment of active polyarticular juvenile idiopathic arthritis (pJIA) [polyarticular rheumatoid factor positive {RF+} or negative {RF-}, extended oligoarticular], in patients 2 years of age and older who have responded inadequately to, or who are intolerant to one or more DMARDs. RINVOQ may be used as monotherapy or in combination with methotrexate.

Axial spondyloarthritis
Non-radiographic axial spondyloarthritis (nr-axSpA)
RINVOQ is indicated for the treatment of active non-radiographic axial spondyloarthritis in adult patients with objective signs of inflammation as indicated by elevated C-reactive protein (CRP) and/or magnetic resonance imaging (MRI), who have responded inadequately to nonsteroidal anti-inflammatory drugs (NSAIDs).

Ankylosing spondylitis (AS, radiographic axial spondyloarthritis)
RINVOQ is indicated for the treatment of active ankylosing spondylitis in adult patients who have responded inadequately to conventional therapy.

Giant cell arteritis
RINVOQ is indicated for the treatment of giant cell arteritis (GCA) in adult patients.

Atopic dermatitis
RINVOQ is indicated for the treatment of moderate to severe atopic dermatitis (AD) in adults and adolescents 12 years and older who are candidates for systemic therapy.

Alopecia areata
RINVOQ is indicated for the treatment of severe alopecia areata in adults and adolescents 12 years and older.

Vitiligo
RINVOQ is indicated for the treatment of non-segmental vitiligo in adults and adolescents 12 years and older who are candidates for systemic therapy.

Ulcerative colitis
RINVOQ is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis (UC) who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent.

Crohn's disease
RINVOQ is indicated for the treatment of adult patients with moderately to severely active Crohn's disease who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent.

Important Safety Information

Contraindications
RINVOQ is contraindicated in patients hypersensitive to the active substance or to any of the excipients, in patients with active tuberculosis (TB) or active serious infections, in patients with severe hepatic impairment, and during pregnancy.

Special warnings and precautions for use
RINVOQ should only be used if no suitable treatment alternatives are available in patients:

- 65 years of age and older;
- patients with history of atherosclerotic cardiovascular (CV) disease or other CV risk factors (such as current or past long-time smokers);
- patients with malignancy risk factors (e.g. current malignancy or history of malignancy).

Use in patients 65 years of age and older
Considering the increased risk of MACE, malignancies, serious infections, and all-cause mortality in patients ≥65 years of age, as observed in a large randomised study of tofacitinib (another Janus Kinase (JAK) inhibitor), RINVOQ should only be used in these patients if no suitable treatment alternatives are available. In patients ≥65 years of age, there is an increased risk of adverse reactions with RINVOQ 30 mg once daily. Consequently, the recommended dose for long-term use in this patient population is 15 mg once daily.

Immunosuppressive medicinal products
Use in combination with other potent immunosuppressants is not recommended.

Serious infections
Serious and sometimes fatal infections have been reported in patients receiving RINVOQ. The most frequent serious infections reported included pneumonia and cellulitis. Cases of bacterial meningitis and sepsis have been reported with RINVOQ. Among opportunistic infections, TB, multidermatomal herpes zoster, oral/esophageal candidiasis, and cryptococcosis have been reported. RINVOQ should not be initiated in patients with an active, serious infection, including localized infections. RINVOQ should be interrupted if a patient develops a serious or opportunistic infection until the infection is controlled. A higher rate of serious infections was observed with RINVOQ 30 mg compared to 15 mg. As there is a higher incidence of infections in the elderly and patients with diabetes in general, caution should be used when treating these populations. In patients ≥65 years of age, RINVOQ should only be used if no suitable treatment alternatives are available.

Tuberculosis
Patients should be screened for TB before starting RINVOQ. RINVOQ should not be given to patients with active TB. Anti-TB therapy may be appropriate for select patients in consultation with a physician with expertise in the treatment of TB. Patients should be monitored for the development of signs and symptoms of TB.

Viral reactivation
Viral reactivation, including cases of herpes zoster, was reported in clinical studies. The risk of herpes zoster appears to be higher in Japanese patients treated with RINVOQ. Consider interruption of RINVOQ if the patient develops herpes zoster until the episode resolves. Screening for viral hepatitis and monitoring for reactivation should occur before and during therapy. If hepatitis B virus DNA is detected, a liver specialist should be consulted.

Vaccination
The use of live, attenuated vaccines during or immediately prior to therapy is not recommended. It is recommended that patients be brought up to date with all immunizations, including prophylactic zoster vaccinations, prior to initiating RINVOQ, in agreement with current immunization guidelines.

Malignancy
Lymphoma and other malignancies have been reported in patients receiving JAK inhibitors, including RINVOQ. In a large randomised active‑controlled study of tofacitinib (another JAK inhibitor) in RA patients ≥50 years of age with ≥1 additional CV risk factor, a higher rate of malignancies, particularly lung cancer, lymphoma, and non-melanoma skin cancer (NMSC), was observed with tofacitinib compared to tumour necrosis factor (TNF) inhibitors. A higher rate of malignancies, including NMSC, was observed with RINVOQ 30 mg compared to 15 mg. Periodic skin examination is recommended for all patients, particularly those with risk factors for skin cancer. In patients ≥65 years of age, patients who are current or past long-time smokers, or patients with other malignancy risk factors (e.g., current malignancy or history of malignancy), RINVOQ should only be used if no suitable treatment alternatives are available.

Hematological abnormalities
Treatment should not be initiated, or should be temporarily interrupted, in patients with hematological abnormalities observed during routine patient management.

Gastrointestinal perforations
Events of diverticulitis and gastrointestinal perforations have been reported in clinical trials and from post marketing sources. RINVOQ should be used with caution in patients who may be at risk for gastrointestinal perforation (e.g., patients with diverticular disease, a history of diverticulitis, or who are taking non-steroidal anti-inflammatory drugs (NSAIDs), corticosteroids, or opioids). Patients with active Crohn's disease are at increased risk for developing intestinal perforation. Patients presenting with new onset abdominal signs and symptoms should be evaluated promptly for early identification of diverticulitis or gastrointestinal perforation.

Major adverse cardiovascular events
MACE were observed in clinical studies of RINVOQ. In a large randomised active-controlled study of tofacitinib (another JAK inhibitor) in RA patients ≥50 years of age with ≥1 additional CV risk factor, a higher rate of MACE, defined as CV death, non-fatal myocardial infarction and non-fatal stroke, was observed with tofacitinib compared to TNF inhibitors. Therefore, in patients ≥65 years of age, patients who are current or past long-time smokers, and patients with history of atherosclerotic CV disease or other CV risk factors, RINVOQ should only be used if no suitable treatment alternatives are available.

Lipids
RINVOQ treatment was associated with dose-dependent increases in lipid parameters, including total cholesterol, low-density lipoprotein cholesterol, and high-density lipoprotein cholesterol.

Hepatic transaminase elevations
Treatment with RINVOQ was associated with an increased incidence of liver enzyme elevation. Hepatic transaminases must be evaluated at baseline and thereafter according to routine patient management. If alanine transaminase (ALT) or aspartate transaminase (AST) increases are observed and drug-induced liver injury is suspected, RINVOQ should be interrupted until this diagnosis is excluded.

Venous thromboembolism
Events of deep venous thrombosis (DVT) and pulmonary embolism (PE) were observed in clinical trials for RINVOQ. In a large randomised active-controlled study of tofacitinib (another JAK inhibitor) in RA patients ≥50 years of age with ≥1 additional CV risk factor, a dose‑dependent higher rate of VTE including DVT and PE was observed with tofacitinib compared to TNF inhibitors. In patients with CV or malignancy risk factors, RINVOQ should only be used if no suitable treatment alternatives are available. In patients with known VTE risk factors other than CV or malignancy risk factors (e.g. previous VTE, patients undergoing major surgery, immobilisation, use of combined hormonal contraceptives or hormone replacement therapy, and inherited coagulation disorder), RINVOQ should be used with caution. Patients should be re-evaluated periodically to assess for changes in VTE risk. Promptly evaluate patients with signs and symptoms of VTE and discontinue RINVOQ in patients with suspected VTE.

Retinal vein occlusion
Retinal vein occlusion has been reported in patients treated with JAK inhibitors, including upadacitinib. Patients should be advised to promptly seek medical care in case they experience symptoms suggestive of retinal vein occlusion.

Hypersensitivity reactions
Serious hypersensitivity reactions such as anaphylaxis and angioedema have been reported in patients receiving RINVOQ. If a clinically significant hypersensitivity reaction occurs, discontinue RINVOQ and institute appropriate therapy.

Hypoglycemia in patients treated for diabetes
There have been reports of hypoglycemia following initiation of JAK inhibitors, including RINVOQ, in patients receiving medication for diabetes. Dose adjustment of anti-diabetic medication may be necessary in the event that hypoglycemia occurs.

Medication residue in stool
Reports of medication residue in stool or ostomy output have occurred in patients taking RINVOQ tablets. Most reports described anatomic (e.g., ileostomy, colostomy, intestinal resection) or functional gastrointestinal conditions with shortened gastrointestinal transit times. Patients should be instructed to contact their healthcare professional if medication residue is observed repeatedly. Patients should be clinically monitored, and alternative treatment should be considered if there is an inadequate therapeutic response.

Giant cell arteritis
RINVOQ monotherapy should not be used for the treatment of acute relapses as efficacy in this setting has not been established. Corticosteroids should be given according to medical judgement and practice guidelines.

Excipients with known effect
RINVOQ 1 mg/ml oral solution contains 0.3 mg sodium benzoate in each ml.

Adverse reactions
The most commonly reported adverse reactions in RA, PsA, and axSpA clinical trials (≥2% of patients in at least one of the indications) with RINVOQ 15 mg were upper respiratory tract infections, blood creatine phosphokinase (CPK) increased, ALT increased, bronchitis, nausea, neutropenia, cough, AST increased, and hypercholesterolemia. Overall, the safety profile observed in patients with psoriatic arthritis or active axial spondyloarthritis treated with RINVOQ 15 mg was consistent with the safety profile observed in patients with RA.

The most commonly reported adverse reactions in AD trials (≥2% of patients) with RINVOQ 15 mg or 30 mg were upper respiratory tract infection, acne, herpes simplex, headache, blood CPK increased, cough, folliculitis, abdominal pain, nausea, neutropenia, pyrexia, and influenza. Dose dependent increased risks of infection and herpes zoster were observed with RINVOQ. The safety profile for RINVOQ 15 mg and 30 mg in adolescents was similar to that in adults. With long-term exposure, skin papilloma was reported in adolescents in the RINVOQ 15 mg and 30 mg groups.

The most commonly reported adverse reactions in the UC and CD trials (≥3% of patients) with RINVOQ 45 mg, 30 mg or 15 mg were upper respiratory tract infection, pyrexia, blood CPK increased, anemia, headache, acne, herpes zoster, neutropenia, rash, pneumonia, hypercholesterolemia, bronchitis, AST increased, fatigue, folliculitis, ALT increased, herpes simplex, and influenza. The overall safety profile observed in patients with UC was generally consistent with that observed in patients with RA. Overall, the safety profile observed in patients with CD treated with RINVOQ was consistent with the known safety profile for RINVOQ.

Overall, the safety profile observed in patients with GCA treated with RINVOQ 15 mg was generally consistent with the known safety profile for RINVOQ.

Overall, the safety profile observed in paediatric patients with pJIA treated with RINVOQ was consistent with the known safety profile of RINVOQ.

The safety profile of RINVOQ 15 mg and 30 mg observed in patients with alopecia areata was generally consistent with the known safety profile in patients with atopic dermatitis.

The safety profile of RINVOQ 15 mg observed in patients with vitiligo was generally consistent with the known safety profile in patients with atopic dermatitis. A higher incidence of hypercholesterolemia was observed in patients with vitiligo treated with RINVOQ 15 mg compared to placebo.

The most common serious adverse reactions were serious infections.

The safety profile of RINVOQ with long term treatment was generally similar to the safety profile during the placebo-controlled period across indications.

RINVOQ is available in 15 mg, 30 mg, and 45 mg prolonged-release tablets and 1 mg/ml oral solution. RINVOQ tablets and RINVOQ oral solution are not bioequivalent. Refer to the Summary of Product Characteristics for posology and method of administration.

This is not a complete summary of all safety information.

See RINVOQ full Summary of Product Characteristics (SmPC) at http://www.ema.europa.eu

Globally, prescribing information varies; refer to the individual country product label for complete information.

About TARGET-CD:
TARGET-CD (M24-885) is a global Phase 2a, multicenter, randomized platform study designed to evaluate multiple investigational targeted therapies, including monotherapy and combination approaches, in adults with moderately to severely active Crohn's disease. The innovative platform design enables evaluation of the efficacy, safety, and mechanistic profiles of different therapeutic strategies using a common comparator, with the goal of rapidly advancing new treatment approaches for patients with Crohn's disease. More information on the TARGET-CD trial can be found at www.clinicaltrials.gov (NCT06548542).

About ABBV-466:
ABBV-466 is an investigational dual-targeting therapy combining risankizumab, an IL-23 inhibitor, with trosunilimab, an α4β7 inhibitor, to address complementary drivers of inflammation in Crohn's disease. The approach is designed to inhibit inflammatory signaling while limiting immune-cell trafficking to the gut, with the goal of achieving deeper disease control than either pathway alone.

ABBV-466 is investigational and its safety and efficacy have not been established by regulatory authorities.

About AbbVie in Immunology
AbbVie is relentless in our pursuit to redefine the standard of care for patients living with immune-mediated conditions, with the goal of helping them live a life free from the limitations of their disease. For nearly 30 years, AbbVie has led and helped shape the field of immunology through groundbreaking science and trusted medicines. Building on deep expertise across gastroenterology, rheumatology and dermatology, and other areas of high unmet need, we continue to invest in a broad and differentiated pipeline – spanning innovative modalities, novel mechanisms of action and next-generation approaches designed to conquer the complex biology underlying immune-mediated disease.

Today, more than 1 million patients worldwide are treated with AbbVie's immunology medicines, approved in more than 175 countries across 20+ immune-mediated diseases that impact adult and pediatric populations. As we work to strengthen our legacy and drive the next wave of innovation, we remain focused on delivering meaningful progress for patients and expanding access to our medicines. For more information, please visit www.abbvie.com/immunology.

About AbbVie
AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas including immunology, neuroscience and oncology – and products and services in our Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on LinkedIn, Facebook, Instagram, X and YouTube.

Forward-Looking Statements
Some statements in this news release are, or may be considered, forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. The words "believe," "expect," "anticipate," "project" and similar expressions and uses of future or conditional verbs, generally identify forward-looking statements. AbbVie cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those expressed or implied in the forward-looking statements. Such risks and uncertainties include, but are not limited to, challenges to intellectual property, competition from other products, difficulties inherent in the research and development process, adverse litigation or government action, changes to laws and regulations applicable to our industry, the impact of global macroeconomic factors, such as economic downturns or uncertainty, international conflict, trade disputes and tariffs, and other uncertainties and risks associated with global business operations. Additional information about the economic, competitive, governmental, technological and other factors that may affect AbbVie's operations is set forth in Item 1A, "Risk Factors," of AbbVie's 2025 Annual Report on Form 10-K, which has been filed with the Securities and Exchange Commission, as updated by its Quarterly Reports on Form 10-Q and in other documents that AbbVie subsequently files with the Securities and Exchange Commission that update, supplement or supersede such information. AbbVie undertakes no obligation, and specifically declines, to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.

References

SKYRIZI. Summary of product characteristics. AbbVie; 2026.SKYRIZI [package insert]. North Chicago, IL: AbbVie Inc.RINVOQ. Summary of product characteristics. AbbVie; 2026.Pipeline. AbbVie. 2026. Accessed September 24, 2026. https://www.abbvie.com/our-science/pipeline.html View original content:https://www.prnewswire.com/news-releases/skyrizi-risankizumab-and-rinvoq-upadacitinib-data-highlight-long-term-clinical-and-endoscopic-outcomes-across-inflammatory-bowel-disease-ibd-at-uegw-2026-302911525.html

SOURCE AbbVie

20 scientific presentations underscore the breadth of AbbVie's leadership in Inflammatory Bowel Disease (IBD) research programs
Latest long-term and real-world data with SKYRIZI®(risankizumab) and RINVOQ® (upadacitinib) provide additional insight into clinical and endoscopic outcomes over approximately three years in moderately to severely active Crohn's disease and ulcerative colitis
New data evaluating endoscopic remission with investigational dual-targeting therapy ABBV-466 in patients with moderate-to-severe Crohn's disease will also be presented

, /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced the presentation of 20 new scientific abstracts from its IBD portfolio at the 2026 United European Gastroenterology (UEG) Week, October 17-20 in Barcelona, Spain. Together, the data reflect the breadth of AbbVie's research across IBD, including established therapies studied over longer treatment periods and in real-world clinical practice.

"Crohn's disease and ulcerative colitis are chronic, lifelong conditions, and understanding how patients respond to treatment over time and in everyday clinical practice is critical," said Sofie Berg, Pharm.D., Ph.D., therapeutic area head, immunology, international medical affairs, AbbVie. "The data presented at UEGW 2026 build on our growing body of evidence that can help clinicians move toward favorable long-term outcomes for people living with IBD."

Key data to be presented include:

Long-term data in moderately to severely active ulcerative colitis (UC) and Crohn's disease (CD) – Open-label extension and post-hoc analyses add to the evidence base for clinical and endoscopic outcomes with risankizumab and upadacitinib

Risankizumab in UC: COMMAND showed sustained clinical and endoscopic outcomes up to three years of maintenance treatment. As-observed clinical remissiona rates of 54.0%–73.1% and endoscopic remissionb rates of 38.8%–53.5% were achieved at week 96 with 180mg across advanced therapy-naïve and advanced therapy-experienced patients.
Upadacitinib in CD: U-ENDURE as-observed analyses showed that clinical and endoscopic outcomes were maintained through approximately four years of treatment. At Week 144, clinical remissionc was achieved by 78.9% of patients receiving 15 mg and 86.6% receiving 30 mg. Endoscopic remissiond was achieved by 47.1% and 64.2% of patients, respectively.

Upadacitinib in the Real World: New Insights from Clinical Practice

Interim results from the real-world UPlift study showed that 70.2% of evaluable patients (N=497) with moderate to severe Crohn's disease achieved clinical responsee with upadacitinib within 12 weeks, with a median time to first response of 13 days.
A real-world claims analysis of patients (N=514) with UC or CD showed that patients who switched from a Tumor Necrosis Factor inhibitor (TNFi) to upadacitinib had lower rates of IBD-related hospitalizations (9.5% vs 16.3%) or surgery (6.9% vs 10.6%) over 12 months compared with patients who cycled to another TNFi.

Additional Findings on Risankizumab Subcutaneous Induction in CD

Data presented at UEGW will further expand on findings from the Phase 3 AFFIRM study evaluating subcutaneous risankizumab induction and maintenance in CD. Following the first presentation of AFFIRM results at the 2026 American College of Gastroenterology Annual Scientific Meeting, the UEGW presentations will provide additional analyses examining outcomes by prior advanced therapy exposure and further characterizing clinical and endoscopic outcomes among patients who responded to subcutaneous risankizumab induction and continued treatment.

aDefined as stool frequency (SF) score ≤ 1, and not greater than baseline, rectal bleeding score = 0, and endoscopic subscore ≤ 1 without evidence of friability.
bDefined as endoscopic subscore = 0.
cDefined as average daily very soft or liquid SF ≤2.8 and average daily abdominal pain (AP) score ≤1.0 and both not greater than induction baseline.
dDefined as Simplified Endoscopic Score for Patients with Crohn's Disease ≤ 4 and at least a 2-point reduction from baseline and no subscore > 1 in any individual variable, as scored by a central reviewer.
eDefined as the first day with ≥30% decrease in daily very soft or liquid SF and/or ≥30% decrease in daily AP score and both not worse than baseline AND a prospective 7-day average daily CR-PRO starting on the first day of daily CR-PRO; prospective 7-day average daily CR-PRO was defined as ≥30% decrease in average daily very soft or liquid SF and/or ≥30% decrease in average daily AP score and both not worse than baseline. Only patients with either baseline SF or AP >0 and both non-missing with at least one postbaseline assessment of CR-PRO2 are included.

The 2026 UEGW Congress program is available here. Select abstracts and oral presentations from AbbVie include:

Presentation Title

Session Details

Efficacy of Risankizumab by Crohn's Disease
Location: Results From 144 Weeks of the
FORTIFY Open-Label Extension Study

Oral

Monday, 19 October

16:00 – 17:00

OP165: Teaching an old dog new tricks:
New implementations of current IBD drug

Efficacy and Safety of Risankizumab
Subcutaneous Induction in Patients With
Moderately to Severely Active Crohn's Disease:
Week 12 Results From the Phase 3 AFFIRM Study

Oral

Monday, 19 October

16:00 – 17:00

OP166: Teaching an old dog new tricks:
New implementations of current IBD drug

Efficacy and Safety of Subcutaneous
Risankizumab Maintenance Therapy Among
Patients With Moderately to Severely Active
Crohn's Disease Who Responded to
Subcutaneous Risankizumab Induction Therapy:
24-Week Results From the AFFIRM Trial

Moderated poster

Monday, 19 October

16:00 – 17:00

MP0087: The IBD exposome: Diet,
environment, and sustainability

Sustained Clinical and Endoscopic Improvements With
up to 3 Years of Risankizumab Maintenance
Treatment in Patients with Moderate to Severe
Ulcerative Colitis Regardless of the Number of Prior
Advanced Therapy Exposures

E-Poster

17-20 October

PP1176

Efficacy and Safety of Upadacitinib Maintenance
Therapy in Moderately to Severely Active
Crohn's Disease: 144-Week Results From the U-
ENDURE Long-Term Extension Study

Oral

Monday, 19 October

11:30 – 12:30

OP108: Long term outcomes
of interventional trials in IBD

Effectiveness of Upadacitinib Treatment in
Moderate to Severe Crohn's Disease in Real-
World Clinical Practice: 6-Month Results From
the UPlift Study

Moderated poster

Sunday, 18 October

09:00 – 10:00

MP0015: Therapeutics in IBD - Real
world experience (3)

Comparative Health Care Resource Use and
Treatment Patterns Following Tumor Necrosis
Factor Inhibitor Cycling Versus Switching to
Upadacitinib: A Propensity Score Matched
Analysis

Oral

Tuesday, 20 October

14:30 – 15:30

OP292: Real world observations in IBD:
Things we don't see in clinical trials

ABBV-466, A Novel Dual-targeting Therapy,
Leads to Endoscopic Remission in Moderate-to-
severe Crohn's Disease: Primary Results and

Molecular Profiling from the Phase 2a TARGET-
CD study

Oral

Monday, 19 October

10:00 – 11:00

LB08: Late-Breaking IBD Trials 

SKYRIZI® (risankizumab) is part of a collaboration between Boehringer Ingelheim and AbbVie, with AbbVie leading development and commercialization globally. 

About SKYRIZI®
SKYRIZI is an interleukin (IL)-23 inhibitor that selectively blocks IL-23 by binding to its p19 subunit. IL-23, a cytokine involved in inflammatory processes, is thought to be linked to a number of chronic immune-mediated diseases.1 SKYRIZI is approved by the U.S. Food and Drug Administration and the European Medicines Agency for the treatment of moderately to severely active plaque psoriasis, psoriatic arthritis, Crohn's disease and ulcerative colitis.1,2

On August 27, 2026, AbbVie announced submission of an application to the European Medicines Agency (EMA) seeking approval of SKYRIZI® for subcutaneous induction for the treatment of adult patients with moderately to severely active CD.

EU Indications and Important Safety Information about SKYRIZI® (risankizumab)1 

Indications

Skyrizi (risankizumab) is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy.

Skyrizi is indicated for the treatment of moderate to severe plaque psoriasis in children and adolescents from the age of 6 years who are candidates for systemic therapy.

Skyrizi, alone or in combination with methotrexate (MTX), is indicated for the treatment of active psoriatic arthritis in adults who have had an inadequate response or who have been intolerant to one or more disease-modifying antirheumatic drugs (DMARDs).

Skyrizi is indicated for the treatment of adult patients with moderately to severely active Crohn's disease who have had an inadequate response to, lost response to, or were intolerant to conventional therapy or a biologic therapy.

Skyrizi is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response to, lost response to, or were intolerant to conventional therapy or a biologic therapy.

Important Safety Information

Risankizumab is contraindicated in patients hypersensitive to the active substance or to any of the excipients, and in patients with clinically important active infections (e.g. active tuberculosis).

Risankizumab may increase the risk of infection. In patients with a chronic infection, a history of recurrent infection, or known risk factors for infection, risankizumab should be used with caution. Treatment with risankizumab should not be initiated in patients with any clinically important active infection until the infection resolves or is adequately treated.

Patients treated with risankizumab should be instructed to seek medical advice if signs or symptoms of clinically important chronic or acute infection occur. If a patient develops such an infection or is not responding to standard therapy for the infection, the patient should be closely monitored and risankizumab should not be administered until the infection resolves.

Prior to initiating treatment with risankizumab, patients should be evaluated for tuberculosis (TB) infection. Patients receiving risankizumab should be monitored for signs and symptoms of active TB. Anti-TB therapy should be considered prior to initiating risankizumab in patients with a past history of latent or active TB in whom an adequate course of treatment cannot be confirmed.

Prior to initiating therapy with risankizumab, completion of all appropriate immunizations should be considered according to current immunization guidelines. If a patient has received live vaccination (viral or bacterial), it is recommended to wait at least 4 weeks prior to starting treatment with risankizumab. Patients treated with risankizumab should not receive live vaccines during treatment and for at least 21 weeks after treatment.

Serious hypersensitivity reactions, including anaphylaxis, have been reported with use of risankizumab. If a serious hypersensitivity reaction occurs, administration of risankizumab should be discontinued immediately and appropriate therapy initiated.

The most frequently reported adverse reactions were upper respiratory infections (13% in psoriasis, 15.6% in Crohn's disease and 26.2% in ulcerative colitis).

Commonly (≥ 1/100 to < 1/10) reported adverse reactions included tinea infections, headache, pruritus, rash, eczema, fatigue, and injection site reactions.

This is not a complete summary of all safety information.

See Skyrizi full Summary of Product Characteristics (SmPC) at http://www.ema.europa.eu 

Globally, prescribing information varies; refer to the individual country product label for complete information.

About RINVOQ® (upadacitinib)
Discovered and developed by AbbVie scientists, RINVOQ is a selective and reversible JAK inhibitor that is being studied in several immune-mediated inflammatory diseases.3,4 In human cellular assays, RINVOQ preferentially inhibits signaling by JAK1 or JAK1/3 with functional selectivity over cytokine receptors that signal via pairs of JAK2.3

Upadacitinib (RINVOQ) is being studied in Phase 3 clinical trials for hidradenitis suppurativa, Takayasu arteritis and systemic lupus erythematosus and in pediatric studies for systemic juvenile idiopathic arthritis, atopic dermatitis, ulcerative colitis and Crohn's disease.

EU Indications and Important Safety Information about RINVOQ® (upadacitinib)3

Indications

Rheumatoid arthritis
RINVOQ is indicated for the treatment of moderate to severe active rheumatoid arthritis (RA) in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs (DMARDs). RINVOQ may be used as monotherapy or in combination with methotrexate.

Psoriatic arthritis
RINVOQ is indicated for the treatment of active psoriatic arthritis (PsA) in adult patients who have responded inadequately to, or who are intolerant to one or more DMARDs. RINVOQ may be used as monotherapy or in combination with methotrexate.

Polyarticular juvenile idiopathic arthritis
RINVOQ is indicated for the treatment of active polyarticular juvenile idiopathic arthritis (pJIA) [polyarticular rheumatoid factor positive {RF+} or negative {RF-}, extended oligoarticular], in patients 2 years of age and older who have responded inadequately to, or who are intolerant to one or more DMARDs. RINVOQ may be used as monotherapy or in combination with methotrexate.

Axial spondyloarthritis
Non-radiographic axial spondyloarthritis (nr-axSpA) 
RINVOQ is indicated for the treatment of active non-radiographic axial spondyloarthritis in adult patients with objective signs of inflammation as indicated by elevated C-reactive protein (CRP) and/or magnetic resonance imaging (MRI), who have responded inadequately to nonsteroidal anti-inflammatory drugs (NSAIDs).

Ankylosing spondylitis (AS, radiographic axial spondyloarthritis)
RINVOQ is indicated for the treatment of active ankylosing spondylitis in adult patients who have responded inadequately to conventional therapy.

Giant cell arteritis
RINVOQ is indicated for the treatment of giant cell arteritis (GCA) in adult patients.

Atopic dermatitis
RINVOQ is indicated for the treatment of moderate to severe atopic dermatitis (AD) in adults and adolescents 12 years and older who are candidates for systemic therapy.

Alopecia areata
RINVOQ is indicated for the treatment of severe alopecia areata in adults and adolescents 12 years and older.

Vitiligo
RINVOQ is indicated for the treatment of non-segmental vitiligo in adults and adolescents 12 years and older who are candidates for systemic therapy.

Ulcerative colitis
RINVOQ is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis (UC) who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent.

Crohn's disease
RINVOQ is indicated for the treatment of adult patients with moderately to severely active Crohn's disease who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent.

Important Safety Information

Contraindications
RINVOQ is contraindicated in patients hypersensitive to the active substance or to any of the excipients, in patients with active tuberculosis (TB) or active serious infections, in patients with severe hepatic impairment, and during pregnancy.

Special warnings and precautions for use
RINVOQ should only be used if no suitable treatment alternatives are available in patients:

- 65 years of age and older;
- patients with history of atherosclerotic cardiovascular (CV) disease or other CV risk factors (such as current or past long-time smokers);
- patients with malignancy risk factors (e.g. current malignancy or history of malignancy).

Use in patients 65 years of age and older
Considering the increased risk of MACE, malignancies, serious infections, and all-cause mortality in patients ≥65 years of age, as observed in a large randomised study of tofacitinib (another Janus Kinase (JAK) inhibitor), RINVOQ should only be used in these patients if no suitable treatment alternatives are available. In patients ≥65 years of age, there is an increased risk of adverse reactions with RINVOQ 30 mg once daily. Consequently, the recommended dose for long-term use in this patient population is 15 mg once daily.

Immunosuppressive medicinal products
Use in combination with other potent immunosuppressants is not recommended.

Serious infections
Serious and sometimes fatal infections have been reported in patients receiving RINVOQ. The most frequent serious infections reported included pneumonia and cellulitis. Cases of bacterial meningitis and sepsis have been reported with RINVOQ. Among opportunistic infections, TB, multidermatomal herpes zoster, oral/esophageal candidiasis, and cryptococcosis have been reported. RINVOQ should not be initiated in patients with an active, serious infection, including localized infections. RINVOQ should be interrupted if a patient develops a serious or opportunistic infection until the infection is controlled. A higher rate of serious infections was observed with RINVOQ 30 mg compared to 15 mg. As there is a higher incidence of infections in the elderly and patients with diabetes in general, caution should be used when treating these populations. In patients ≥65 years of age, RINVOQ should only be used if no suitable treatment alternatives are available.

Tuberculosis
Patients should be screened for TB before starting RINVOQ. RINVOQ should not be given to patients with active TB. Anti-TB therapy may be appropriate for select patients in consultation with a physician with expertise in the treatment of TB. Patients should be monitored for the development of signs and symptoms of TB.

Viral reactivation
Viral reactivation, including cases of herpes zoster, was reported in clinical studies. The risk of herpes zoster appears to be higher in Japanese patients treated with RINVOQ. Consider interruption of RINVOQ if the patient develops herpes zoster until the episode resolves. Screening for viral hepatitis and monitoring for reactivation should occur before and during therapy. If hepatitis B virus DNA is detected, a liver specialist should be consulted.

Vaccination
The use of live, attenuated vaccines during or immediately prior to therapy is not recommended. It is recommended that patients be brought up to date with all immunizations, including prophylactic zoster vaccinations, prior to initiating RINVOQ, in agreement with current immunization guidelines.

Malignancy
Lymphoma and other malignancies have been reported in patients receiving JAK inhibitors, including RINVOQ. In a large randomised active‑controlled study of tofacitinib (another JAK inhibitor) in RA patients ≥50 years of age with ≥1 additional CV risk factor, a higher rate of malignancies, particularly lung cancer, lymphoma, and non-melanoma skin cancer (NMSC), was observed with tofacitinib compared to tumour necrosis factor (TNF) inhibitors. A higher rate of malignancies, including NMSC, was observed with RINVOQ 30 mg compared to 15 mg. Periodic skin examination is recommended for all patients, particularly those with risk factors for skin cancer. In patients ≥65 years of age, patients who are current or past long-time smokers, or patients with other malignancy risk factors (e.g., current malignancy or history of malignancy), RINVOQ should only be used if no suitable treatment alternatives are available.

Hematological abnormalities
Treatment should not be initiated, or should be temporarily interrupted, in patients with hematological abnormalities observed during routine patient management.

Gastrointestinal perforations
Events of diverticulitis and gastrointestinal perforations have been reported in clinical trials and from post marketing sources. RINVOQ should be used with caution in patients who may be at risk for gastrointestinal perforation (e.g., patients with diverticular disease, a history of diverticulitis, or who are taking non-steroidal anti-inflammatory drugs (NSAIDs), corticosteroids, or opioids). Patients with active Crohn's disease are at increased risk for developing intestinal perforation. Patients presenting with new onset abdominal signs and symptoms should be evaluated promptly for early identification of diverticulitis or gastrointestinal perforation.

Major adverse cardiovascular events
MACE were observed in clinical studies of RINVOQ. In a large randomised active-controlled study of tofacitinib (another JAK inhibitor) in RA patients ≥50 years of age with ≥1 additional CV risk factor, a higher rate of MACE, defined as CV death, non-fatal myocardial infarction and non-fatal stroke, was observed with tofacitinib compared to TNF inhibitors. Therefore, in patients ≥65 years of age, patients who are current or past long-time smokers, and patients with history of atherosclerotic CV disease or other CV risk factors, RINVOQ should only be used if no suitable treatment alternatives are available.

Lipids
RINVOQ treatment was associated with dose-dependent increases in lipid parameters, including total cholesterol, low-density lipoprotein cholesterol, and high-density lipoprotein cholesterol.

Hepatic transaminase elevations
Treatment with RINVOQ was associated with an increased incidence of liver enzyme elevation. Hepatic transaminases must be evaluated at baseline and thereafter according to routine patient management. If alanine transaminase (ALT) or aspartate transaminase (AST) increases are observed and drug-induced liver injury is suspected, RINVOQ should be interrupted until this diagnosis is excluded.

Venous thromboembolism
Events of deep venous thrombosis (DVT) and pulmonary embolism (PE) were observed in clinical trials for RINVOQ. In a large randomised active-controlled study of tofacitinib (another JAK inhibitor) in RA patients ≥50 years of age with ≥1 additional CV risk factor, a dose‑dependent higher rate of VTE including DVT and PE was observed with tofacitinib compared to TNF inhibitors. In patients with CV or malignancy risk factors, RINVOQ should only be used if no suitable treatment alternatives are available. In patients with known VTE risk factors other than CV or malignancy risk factors (e.g. previous VTE, patients undergoing major surgery, immobilisation, use of combined hormonal contraceptives or hormone replacement therapy, and inherited coagulation disorder), RINVOQ should be used with caution. Patients should be re-evaluated periodically to assess for changes in VTE risk. Promptly evaluate patients with signs and symptoms of VTE and discontinue RINVOQ in patients with suspected VTE.

Retinal vein occlusion
Retinal vein occlusion has been reported in patients treated with JAK inhibitors, including upadacitinib. Patients should be advised to promptly seek medical care in case they experience symptoms suggestive of retinal vein occlusion.

Hypersensitivity reactions
Serious hypersensitivity reactions such as anaphylaxis and angioedema have been reported in patients receiving RINVOQ. If a clinically significant hypersensitivity reaction occurs, discontinue RINVOQ and institute appropriate therapy.

Hypoglycemia in patients treated for diabetes
There have been reports of hypoglycemia following initiation of JAK inhibitors, including RINVOQ, in patients receiving medication for diabetes. Dose adjustment of anti-diabetic medication may be necessary in the event that hypoglycemia occurs.

Medication residue in stool
Reports of medication residue in stool or ostomy output have occurred in patients taking RINVOQ tablets. Most reports described anatomic (e.g., ileostomy, colostomy, intestinal resection) or functional gastrointestinal conditions with shortened gastrointestinal transit times. Patients should be instructed to contact their healthcare professional if medication residue is observed repeatedly. Patients should be clinically monitored, and alternative treatment should be considered if there is an inadequate therapeutic response.

Giant cell arteritis
RINVOQ monotherapy should not be used for the treatment of acute relapses as efficacy in this setting has not been established. Corticosteroids should be given according to medical judgement and practice guidelines.

Excipients with known effect
RINVOQ 1 mg/ml oral solution contains 0.3 mg sodium benzoate in each ml.

Adverse reactions
The most commonly reported adverse reactions in RA, PsA, and axSpA clinical trials (≥2% of patients in at least one of the indications) with RINVOQ 15 mg were upper respiratory tract infections, blood creatine phosphokinase (CPK) increased, ALT increased, bronchitis, nausea, neutropenia, cough, AST increased, and hypercholesterolemia. Overall, the safety profile observed in patients with psoriatic arthritis or active axial spondyloarthritis treated with RINVOQ 15 mg was consistent with the safety profile observed in patients with RA.

The most commonly reported adverse reactions in AD trials (≥2% of patients) with RINVOQ 15 mg or 30 mg were upper respiratory tract infection, acne, herpes simplex, headache, blood CPK increased, cough, folliculitis, abdominal pain, nausea, neutropenia, pyrexia, and influenza. Dose dependent increased risks of infection and herpes zoster were observed with RINVOQ. The safety profile for RINVOQ 15 mg and 30 mg in adolescents was similar to that in adults. With long-term exposure, skin papilloma was reported in adolescents in the RINVOQ 15 mg and 30 mg groups.

The most commonly reported adverse reactions in the UC and CD trials (≥3% of patients) with RINVOQ 45 mg, 30 mg or 15 mg were upper respiratory tract infection, pyrexia, blood CPK increased, anemia, headache, acne, herpes zoster, neutropenia, rash, pneumonia, hypercholesterolemia, bronchitis, AST increased, fatigue, folliculitis, ALT increased, herpes simplex, and influenza. The overall safety profile observed in patients with UC was generally consistent with that observed in patients with RA. Overall, the safety profile observed in patients with CD treated with RINVOQ was consistent with the known safety profile for RINVOQ.

Overall, the safety profile observed in patients with GCA treated with RINVOQ 15 mg was generally consistent with the known safety profile for RINVOQ.

Overall, the safety profile observed in paediatric patients with pJIA treated with RINVOQ was consistent with the known safety profile of RINVOQ.

The safety profile of RINVOQ 15 mg and 30 mg observed in patients with alopecia areata was generally consistent with the known safety profile in patients with atopic dermatitis.

The safety profile of RINVOQ 15 mg observed in patients with vitiligo was generally consistent with the known safety profile in patients with atopic dermatitis. A higher incidence of hypercholesterolemia was observed in patients with vitiligo treated with RINVOQ 15 mg compared to placebo.

The most common serious adverse reactions were serious infections.

The safety profile of RINVOQ with long term treatment was generally similar to the safety profile during the placebo-controlled period across indications.

RINVOQ is available in 15 mg, 30 mg, and 45 mg prolonged-release tablets and 1 mg/ml oral solution. RINVOQ tablets and RINVOQ oral solution are not bioequivalent. Refer to the Summary of Product Characteristics for posology and method of administration.

This is not a complete summary of all safety information.

See RINVOQ full Summary of Product Characteristics (SmPC) at http://www.ema.europa.eu 

Globally, prescribing information varies; refer to the individual country product label for complete information.

About TARGET-CD:
TARGET-CD (M24-885) is a global Phase 2a, multicenter, randomized platform study designed to evaluate multiple investigational targeted therapies, including monotherapy and combination approaches, in adults with moderately to severely active Crohn's disease. The innovative platform design enables evaluation of the efficacy, safety, and mechanistic profiles of different therapeutic strategies using a common comparator, with the goal of rapidly advancing new treatment approaches for patients with Crohn's disease. More information on the TARGET-CD trial can be found at www.clinicaltrials.gov (NCT06548542).

About ABBV-466:
ABBV-466 is an investigational dual-targeting therapy combining risankizumab, an IL-23 inhibitor, with trosunilimab, an α4β7 inhibitor, to address complementary drivers of inflammation in Crohn's disease. The approach is designed to inhibit inflammatory signaling while limiting immune-cell trafficking to the gut, with the goal of achieving deeper disease control than either pathway alone.

ABBV-466 is investigational and its safety and efficacy have not been established by regulatory authorities.

About AbbVie in Immunology
AbbVie is relentless in our pursuit to redefine the standard of care for patients living with immune-mediated conditions, with the goal of helping them live a life free from the limitations of their disease. For nearly 30 years, AbbVie has led and helped shape the field of immunology through groundbreaking science and trusted medicines. Building on deep expertise across gastroenterology, rheumatology and dermatology, and other areas of high unmet need, we continue to invest in a broad and differentiated pipeline – spanning innovative modalities, novel mechanisms of action and next-generation approaches designed to conquer the complex biology underlying immune-mediated disease.

Today, more than 1 million patients worldwide are treated with AbbVie's immunology medicines, approved in more than 175 countries across 20+ immune-mediated diseases that impact adult and pediatric populations. As we work to strengthen our legacy and drive the next wave of innovation, we remain focused on delivering meaningful progress for patients and expanding access to our medicines. For more information, please visit www.abbvie.com/immunology.

About AbbVie
AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas including immunology, neuroscience and oncology – and products and services in our Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on LinkedIn, Facebook, Instagram, X and YouTube.

Forward-Looking Statements
Some statements in this news release are, or may be considered, forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. The words "believe," "expect," "anticipate," "project" and similar expressions and uses of future or conditional verbs, generally identify forward-looking statements. AbbVie cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those expressed or implied in the forward-looking statements. Such risks and uncertainties include, but are not limited to, challenges to intellectual property, competition from other products, difficulties inherent in the research and development process, adverse litigation or government action, changes to laws and regulations applicable to our industry, the impact of global macroeconomic factors, such as economic downturns or uncertainty, international conflict, trade disputes and tariffs, and other uncertainties and risks associated with global business operations. Additional information about the economic, competitive, governmental, technological and other factors that may affect AbbVie's operations is set forth in Item 1A, "Risk Factors," of AbbVie's 2025 Annual Report on Form 10-K, which has been filed with the Securities and Exchange Commission, as updated by its Quarterly Reports on Form 10-Q and in other documents that AbbVie subsequently files with the Securities and Exchange Commission that update, supplement or supersede such information. AbbVie undertakes no obligation, and specifically declines, to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.

References

SKYRIZI. Summary of product characteristics. AbbVie; 2026.
SKYRIZI [package insert]. North Chicago, IL: AbbVie Inc.
RINVOQ. Summary of product characteristics. AbbVie; 2026.
Pipeline. AbbVie. 2026. Accessed September 24, 2026. https://www.abbvie.com/our-science/pipeline.html

SOURCE AbbVie

As the healthcare sector evolves, investors often choose between growth-oriented leaders and established dividend payers. Deciding between AbbVie (ABBV +2.23%) and Pfizer (PFE +1.51%) requires understanding how these giants manage patent transitions and new drug pipelines.

AbbVie specializes in immunology and oncology treatments, while Pfizer maintains a massive global footprint in vaccines and primary care. Both companies face intense regulatory scrutiny and competition from generic manufacturers. Comparing them helps identify which business model offers the most stability for your long-term portfolio during the current fiscal period.

The case for AbbVieAbbVie is a research-driven biopharmaceutical firm that focuses on delivering innovative medicines for complex health issues. The company distributes its pharmaceutical products primarily through three major U.S. wholesale distributors: McKesson (MCK +1.64%), Cardinal Health (CAH +1.23%), and Cencora (COR +1.87%). These entities collectively account for substantially all of the company's domestic pharmaceutical sales. Customer concentration like this adds a layer of risk to the business, though the company notes that losing any single customer would not be materially adverse.

In FY 2025, revenue reached nearly $61.2 billion, representing growth of approximately 8.6% compared to the previous year. This upward trend highlights the company's ability to expand its portfolio even as older drugs face competition. The company reported net income of approximately $4.2 billion for the same period. While income was slightly lower than the prior year, the company maintained a net margin of 6.9%.

As of its December 2025 balance sheet, the company reported a debt-to-equity ratio of -21.1x. This value means that total liabilities exceed shareholder equity. The current ratio, which compares short-term assets to short-term obligations, was approximately 0.7x. Free cash flow, or the cash remaining after paying for operations and equipment, reached nearly $17.8 billion in FY 2025. This strong cash generation provides the capital necessary for research and development.

The case for PfizerPfizer operates as a global biopharmaceutical giant, applying advanced science to discover and manufacture vaccines and medicines. The company sells its products in approximately 200 countries and relies heavily on managed care entities and pharmacy benefit managers. This reliance makes it a key player among pharmaceutical stocks as it manages pricing pressures. Consolidation among major pharmacy chains has increased the leverage these customers hold over drug pricing.

In FY 2025, revenue reached nearly $62.6 billion, which was a decrease of approximately 1.6% from the previous year. This decline reflects the normalization of sales following the peak of pandemic-related product demand. Despite the revenue dip, net income for the period was close to $7.8 billion. This resulted in a net margin of 12.4%, showing the company's ability to maintain high profitability during a transition phase.

As of its December 2025 balance sheet, the debt-to-equity ratio was nearly 0.8x. This metric compares total debt to shareholder equity to show how much a firm relies on borrowing to fund its operations. The current ratio was roughly 1.2x, suggesting the company has a solid cushion of liquid assets. Free cash flow reached close to $9.1 billion in FY 2025. This cash flow supports ongoing efforts to integrate new acquisitions into the pipeline.

Risk profile comparisonAbbVie faces significant revenue erosion as biosimilar competition targets its legacy products, particularly after patent expirations. The business also navigates the impact of the Inflation Reduction Act, which subjects key products like Imbruvica, Vraylar, Linzess, and Botox to government-set pricing. Furthermore, the company relies heavily on Skyrizi and Rinvoq, which together accounted for nearly 42% of its 2025 net revenues. Legal challenges also persist, including an October 2026 action by the American Hospital Association regarding drug pricing programs.

Pfizer deals with aggressive product launches from competitors and biosimilar pressure on its established brands. Legislative changes like the Inflation Reduction Act have already impacted revenues for products such as Eliquis, Ibrance, Xtandi, and Xeljanz. Litigation remains a factor, following a confidential August 2026 settlement regarding Depo-Provera and a separate $44 million Chantix settlement. Additionally, the company must successfully integrate its 2026 Metsera acquisition to strengthen its position in the obesity-treatment market.

Valuation comparisonPfizer appears to be the more value-oriented choice based on its lower multiples. The Forward P/E compares the current share price to future earnings estimates. Meanwhile, the P/S ratio measures market capitalization relative to sales over the past twelve months.

MetricAbbViePfizerForward P/E20.3x9.9xP/S ratio7.8x2.6xValuation metrics include sourcing from Financial Modeling Prep (FMP) and may differ from other data providers.

I'd go with AbbVie, though Pfizer is also worth taking seriously right now. Both are navigating the same fundamental challenge of replacing revenue from drugs losing patent protection.

But AbbVie has already done the hard thing. For years, investors worried that cheaper competing versions of Humira entering the market would devastate the business. Instead, Skyrizi and Rinvoq have more than filled the gap, growing at a pace that keeps pushing management to raise its full-year outlook. The neuroscience portfolio is accelerating in ways that add a second major growth engine, and a growing dividend makes the wait more comfortable for patient shareholders.

Pfizer is playing a longer game. Non-COVID products are growing at a steady clip and several key pipeline readouts are expected over the next 12 months. Its acquisition of Metsera puts it in the obesity drug race alongside Eli Lilly and Novo Nordisk. Management has committed to protecting the dividend through the transition.

The difference here is that AbbVie has already navigated its toughest stretch and kept growing through it. For investors who want pharmaceutical exposure today rather than a bet on when Pfizer turns the corner, AbbVie is the clearer choice.

Sanofi's upgraded 2026 outlook, Dupixent growth and attractive valuation give it an edge over AbbVie, despite pipeline setbacks and vaccine sales challenges.

On October 13, 2026, AbbVie Inc ABBV shares fell 2.4% to a current price of $274.36. This decline occurs within a wider 52-week range of $190.75 to $283.43, reflecting a year characterized by significant volatility and growth.

GF Value™ verdict indicates the stock is trading at a premium, with a fair value estimate of $222.10, suggesting it is 23.5% overvalued. GF Score™ of 76/100 categorizes AbbVie as above average, indicating a generally favorable assessment relative to its peers. Notable signal: Insiders have sold $17.7 million worth of shares in the past 12 months, with no buying activity reported.Is ABBV Overvalued or Undervalued?AbbVie Inc's current price of $274.36 stands significantly above its GF Value™ estimate of $222.10, positioning the stock as overvalued by approximately 23.5%. The GF Value™ is GuruFocus' proprietary intrinsic-value estimate, which takes into account historical trading multiples, past business growth, and projections of future performance. With the GF Valuation label indicating that AbbVie is "Modestly Overvalued," there is a clear risk for shareholders, particularly in a market where valuations can swiftly adjust to reflect underlying business fundamentals.

The margin of safety appears limited for potential investors, as the gap between the current market price and the estimated fair value suggests that buying at this level may not provide a sufficient buffer against downturns. This overvaluation requires careful consideration, especially in light of AbbVie's financial health and market dynamics.

How Does ABBV's Valuation Compare to Its History?Metric Current Historical P/E (TTM) 77.6x 57.0x Forward P/E 16.9x -AbbVie's current P/E (TTM) of 77.6x is notably higher than its 5-year median P/E of 57.0x, indicating that the stock is trading at a 36% premium compared to its historical valuation metrics. Additionally, the forward P/E of 16.9x may suggest a more favorable outlook, yet this figure does not mitigate the current overvaluation highlighted by the GF Value™. Overall, the P/E analysis aligns with the GF Value™ verdict by supporting the notion that AbbVie is overvalued in the current market environment.

What Does ABBV's GF Score™ Tell Us?The GF Score™ evaluates a stock's overall quality based on various factors, including financial strength, profitability, growth potential, valuation, and momentum. AbbVie’s GF Score™ of 76/100 reflects its strong performance, particularly in profitability, while indicating some weaknesses in financial strength and momentum.

Metric Rating GF Score™ 76/100 Financial Strength 4/10 Profitability 9/10 Growth 6/10 Valuation 5/10 Momentum 3/10AbbVie excels in profitability with a high score of 9/10, demonstrating its ability to generate strong earnings. However, the company's financial strength score of 4/10 indicates potential vulnerabilities that could impact its stability. The growth and valuation ranks of 6/10 and 5/10, respectively, suggest a moderate outlook, while the low momentum rank of 3/10 could point to challenges in maintaining upward price movement in the current market climate.

What Are Gurus and Insiders Doing with ABBV?Currently, 18 gurus hold positions in AbbVie, with 8 adding to their stakes and 8 trimming their positions in recent quarters. This balanced activity among gurus reflects a mixed sentiment regarding the stock's potential. Notably, insiders have sold $17.7 million worth of shares over the last year without any buying activity, which may signal a lack of confidence in the stock's short-term performance or valuation.

The insider selling trend could raise concerns for potential investors, as it suggests that those closest to the company may not view the current price as attractive for holding shares. This pattern should be taken into account when deciding on an investment strategy in relation to AbbVie.

What This Means for InvestorsIn conclusion, AbbVie Inc ABBV appears to be overvalued based on the GF Value™ assessment, which indicates that current prices exceed intrinsic value by 23.5%. While the company's strong profitability metrics may attract some investors, the signals from insider activity and the modestly overvalued status suggest caution. Understanding these dynamics is key for making informed decisions in the stock market. For further details, you can visit the AbbVie Inc (ABBV) stock page and explore the GF Value™ page for additional insights.

Frequently Asked QuestionsWhat is ABBV's GF Score™?

ABBV has a GF Score™ of 76/100, indicating it is considered above average in quality among its peers.

Is ABBV overvalued or undervalued?

ABBV is currently overvalued, with a GF Value™ estimate of $222.10 compared to its market price of $274.36.

What is ABBV's P/E ratio?

ABBV's P/E (TTM) ratio is 77.6x, which is significantly higher than its 5-year median P/E of 57.0x, indicating it is trading at a premium compared to its historical valuation.

This stock alert was generated using automated technology and GuruFocus financial data to provide readers with timely and accurate market reporting. This content was reviewed by GuruFocus editorial team prior to publication. Please send any questions or comments about this story to [email protected].

Disclosures
I/We may personally own shares in some of the companies mentioned above. However, those positions are not material to either the company or to my/our portfolios.

Two of these five dividend stocks just took a beating in October, and that selloff quietly pushed their yields to levels that make the safer-looking names on the list look stingy by comparison.

A big yield only matters if the business can keep paying it. Every name on this month’s list pays its dividend out of cash generation that clearly tops the dividend bill, and each has years of increases to show for it. Verizon (NYSE:VZ | VZ Price Prediction) is the clearest example. It guides to $21.94B to $22.14B of 2026 free cash flow, while its forward dividend costs about $11.76B a year. Here are five NYSE-listed income names where the payout rests on cash flow. Two of them are trading lower right now, which has pushed their yields up.

Realty Income: Monthly Payer Near Its 52-Week Low Realty Income (NYSE:O) yields about 5.98%, based on its $3.258 annualized forward dividend and a share price of $54.44. That makes it high-yield, sitting just under the ultra-high-yield line. The latest monthly payment of $0.2715 goes out on October 15, 2026.

Dividend safety: Management raised 2026 AFFO (adjusted funds from operations, the REIT version of cash earnings) guidance to $4.44 to $4.45 per share. At the low end of that range, the forward dividend uses about 73% of AFFO. Q2 AFFO per share came in at $1.09, up 3.8% year over year, and occupancy stands at 98.8%. Fitch rates the company “A” with a stable outlook. The Q2 release marked the 115th consecutive quarterly dividend increase, and the company had declared 670 consecutive monthly dividends as of its Q1 report.

Bull case: The stock is down 8.05% over the past month. It now trades below its 50-day average of $59.47 and its 200-day average of $61.74, close to its 52-week low of $53.15. Meanwhile, the business keeps growing. Management raised 2026 investment volume to $10.0B, renewed leases are coming in at 102.7% of prior rent, and a $6B hyperscale data center joint venture adds a new growth channel. The average analyst target is $66.39.

Risk: Tenants without investment-grade credit generate 65.7% of annualized base rent. Net debt to adjusted EBITDAre also rose to 5.4x from 5.2x in Q1, so the REIT is more exposed if interest rates stay high.

AbbVie: Dividend Growth Backed by Skyrizi and Rinvoq AbbVie (NYSE:ABBV) yields about 2.49% on a $6.92 forward dividend. That is the lowest yield on this list. AbbVie is here for dividend growth, and the record backs that up. To get the next $1.73 quarterly payment, you must own shares before the October 15, 2026 ex-dividend date.

Dividend safety: AbbVie has raised its dividend every year since its 2013 spin-off. The quarterly payment went from $0.40 in 2013 to $1.73 in 2026. Full-year adjusted EPS guidance is $13.87 to $14.07, so the forward dividend uses about 50% of the low end. Q2 adjusted EPS of $3.65 beat the $3.08 consensus. The CFO said the company remains committed to “achieving a net leverage ratio of two times within two to three years following the deal close.”

Bull case: Newer drugs are making up for Humira’s lost sales. Skyrizi grew 24.4% to $5.51B and Rinvoq grew 24.5% to $2.53B. Management now expects full-year revenue of about $67.6 billion. The stock trades at 16 times forward earnings and is up 24.57% year to date.

Risk: Humira sales dropped 35.9% to $756M, and Imbruvica fell 29.4%. The pending $10.9B immunology acquisition is expected to reduce earnings by $0.14 per share and will add more debt to a balance sheet that already shows negative book value.

Verizon: Ultra-High Yield After a Sharp Selloff Verizon is an ultra-high-yield name at about 6.58%, based on a $2.83 forward dividend and a $43 share price. Part of that yield comes from a recent drop. The stock is down 13.59% over one month, and telecom stocks bounced only slightly on Monday after Friday’s plunge.

Dividend safety: Free cash flow covers the dividend easily. Q2 free cash flow rose 27.1% to $6.43B, and the adjusted EBITDA margin expanded to 40.1% from 37.1%. The quarterly payment went up from $0.69 to $0.7075 in 2026. Verizon’s dividend history shows continuous quarterly payments since 1999, rising from $0.385 per quarter at the start. After the Frontier deal, net unsecured debt rose to 2.5x adjusted EBITDA.

Bull case: The core business is improving. Verizon added 184K postpaid phone subscribers, compared with a loss of 9K a year earlier. Churn (the share of customers leaving) improved to 0.92%, and fiber connections rose 43.3% to 10.9M. Management raised adjusted EPS guidance to $4.99 to $5.04. At 9 times forward earnings, the stock trades well below the average analyst target of $51.24.

Risk: Competition is the main threat. Fixed wireless net adds fell 30.6% and GAAP net income dropped 22.9%. Higher debt after Frontier also leaves less room for mistakes if a price war breaks out.

Chevron: Record Production and Hess Cash Cover the Payout Chevron (NYSE:CVX) yields about 3.28%, based on a $1.78 quarterly dividend and a $217.18 share price. The yield is lower than it was because the stock has risen 46.46% year to date.

Dividend safety: Q2 adjusted free cash flow was $15.4 billion. The quarterly dividend costs about $3.49B, so cash flow covered it several times over. Chevron paid down more than $8 billion of debt in the quarter. Net debt to EBITDA is 0.94x and interest coverage is 13.7x. The quarterly dividend has gone up every year from 2017 through 2026, from $1.08 to $1.78. The CEO said the Hess assets generate free cash flow “roughly double the incremental dividends.”

Bull case: Chevron hit a record 2,077 MBOED of U.S. upstream production. It reached $3 billion in structural cost cuts six months ahead of schedule. It also signed a 20-year take-or-pay power contract for 2.67 gigawatts to supply an AI data center, which brings in cash that does not depend on oil prices. Management’s 2030 targets assume “flat commodity prices that are lower than today.”

Risk: High oil prices lifted Q2 results. Brent averaged $104 in the quarter versus $68 a year earlier. If oil falls back, the cash buffer over the dividend will contract.

Altria: A Raised Payout Facing Shrinking Cigarette Volumes Altria (NYSE:MO) is ultra-high-yield at about 6.24%, based on its $4.44 annualized dividend and a $71.16 share price. In August, the board raised the quarterly payment 4.7% to $1.11, which the company called “the 61st dividend increase in the past 57 years.”

Dividend safety: Adjusted EPS guidance is $5.61 to $5.72, so the dividend uses about 79% of the low end. That is a high payout ratio, but Altria has run at that level for years. Management is aiming mid-single digits dividend per share growth annually through 2028. Altria returned nearly $3.9B to shareholders in the first half of 2026. Shareholders’ equity is negative at -$2.6B, mainly because of years of buybacks.

Bull case: Pricing power keeps cigarette profits strong even as volumes fall. on! PLUS is now in 120,000 stores. At 12 times forward earnings, the stock has a modest valuation. The stock is up 29.4% year to date.

Risk: Domestic cigarette volumes fell 5%, Marlboro’s retail share slid to 39.5%, and on! lost 4.2 pts of nicotine pouch share. The stock also trades above the average analyst target of $70.

One Roster, Five Sources of Cash Realty Income and Verizon have fallen in price while their cash flow keeps growing. Chevron brings the strongest balance sheet on the list, and AbbVie brings a dividend-growth record dating back to its spin-off. Altria rounds it out with an ultra-high yield and a long history of increases. Each payout is supported by cash generation, and the next round of quarterly results will show whether that coverage holds.

Contact [email protected] for any questions or corrections.

In the latest close session, AbbVie (ABBV - Free Report) was up +1.65% at $281.04. This change outpaced the S&P 500's 0.06% loss on the day. Elsewhere, the Dow saw an upswing of 0.38%, while the tech-heavy Nasdaq depreciated by 0.44%.

Shares of the drugmaker have appreciated by 7.53% over the course of the past month, outperforming the Medical sector's gain of 0.04%, and the S&P 500's gain of 2.36%.

Market participants will be closely following the financial results of AbbVie in its upcoming release. The company plans to announce its earnings on October 30, 2026. The company is predicted to post an EPS of $3.8, indicating a 104.3% growth compared to the equivalent quarter last year. Meanwhile, our latest consensus estimate is calling for revenue of $17.36 billion, up 10.01% from the prior-year quarter.

For the full year, the Zacks Consensus Estimates are projecting earnings of $13.98 per share and revenue of $67.63 billion, which would represent changes of +39.8% and +10.57%, respectively, from the prior year.

Additionally, investors should keep an eye on any recent revisions to analyst forecasts for AbbVie. These revisions typically reflect the latest short-term business trends, which can change frequently. With this in mind, we can consider positive estimate revisions a sign of optimism about the business outlook.

Our research reveals that these estimate alterations are directly linked with the stock price performance in the near future. To take advantage of this, we've established the Zacks Rank, an exclusive model that considers these estimated changes and delivers an operational rating system.

The Zacks Rank system, running from #1 (Strong Buy) to #5 (Strong Sell), holds an admirable track record of superior performance, independently audited, with #1 stocks contributing an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has moved 0.79% lower. Currently, AbbVie is carrying a Zacks Rank of #4 (Sell).

In terms of valuation, AbbVie is presently being traded at a Forward P/E ratio of 19.77. This signifies a premium in comparison to the average Forward P/E of 16.16 for its industry.

It's also important to note that ABBV currently trades at a PEG ratio of 1.26. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. ABBV's industry had an average PEG ratio of 1.91 as of yesterday's close.

The Large Cap Pharmaceuticals industry is part of the Medical sector. With its current Zacks Industry Rank of 193, this industry ranks in the bottom 22% of all industries, numbering over 250.

The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

You can find more information on all of these metrics, and much more, on Zacks.com.

Skyrizi and Rinvoq are growing fast, a blockbuster acquisition just closed, and the FDA handed AbbVie a fresh approval, yet the stock sits just shy of a price target that has Wall Street divided between a $297 bull case and…

AbbVie (NYSE:ABBV | ABBV Price Prediction) trades at $277.15 midday Friday. Our 24/7 Wall St. price target is $279.12 over 12 months, representing 2.46% upside from the model price.

Our high confidence reflects broad growth: Skyrizi, Rinvoq and neuroscience each delivered growth above 20% last quarter. AbbVie completed its Apogee Therapeutics acquisition on September 3, 2026. The stock sits near the $280.79 consensus target, limiting upside.

A Breakout Above the 52-Week High Shows Momentum Building Shares rose 6.62% over the past week, 11.4% over the past month and 24.16% year to date, breaking above the prior 52-week high of $274.94.

Second-quarter revenue of $16.99 billion rose 10.2%, ahead of the $16.76 billion consensus. Adjusted EPS of $3.65 met the $3.64 estimate. Management raised revenue guidance by $300 million to about $67.6 billion. The FDA approved JUVMO (tavapadon) for Parkinson’s disease, and Temab-A received two Breakthrough Therapy Designations.

Why Bulls See $297 Within Reach Skyrizi sales reached $5.51 billion last quarter, up 24.4%, with management expecting $21.7 billion for the full year. Rinvoq peak sales in vitiligo and alopecia areata alone could approach $2 billion. Apogee’s zumilokibart posted positive Phase 2 results in atopic dermatitis, positioning it as a credible billion-dollar candidate.

A new under-the-skin Skyrizi dose for Crohn’s disease could accelerate growth starting “really early in 27”. Wall Street gives 8 Strong Buy and 16 Buy ratings to the stock. The bull case reaches $297.77.

Humira Erosion and Debt Keep Risks on the Table Humira sales fell 35.9% to $756 million, and Imbruvica dropped 29.4%. Net debt stands at 2.26x EBITDA. The trailing P/E of 114 reflects $5 billion in acquired R&D charges in 2025.

On forward earnings, the stock trades at 16x. Management targets two times net leverage within two to three years. Our bear case is $246.52.

How AbbVie Compares to Merck and Eli Lilly Company Forward P/E Quarterly Revenue Growth (YoY) AbbVie 16x 10.2% Merck 15x 5.1% Eli Lilly 24x 47.7% Merck (NYSE:MRK) faces a similar patent cliff. Keytruda sales of $7.904 billion declined 1%. Merck trades at a discount to AbbVie, which makes sense given AbbVie’s faster growth.

Eli Lilly (NYSE:LLY) competes in immunology through Ebglyss, whose sales rose 131%. Lilly’s premium multiple reflects much faster growth. AbbVie sits between both peers.

AbbVie Price Prediction 2026-2030 Our 24/7 Wall St. price target of $279.12 carries a hold rating and 90% confidence. After the rally, valuation has caught up with fundamentals. Approval of the Skyrizi Crohn’s dose or strong Rinvoq dermatology launches could turn positive.

Accelerating Humira declines or higher Apogee integration costs would call for caution. For now, AbbVie looks fairly valued.

The 24/7 Wall St. price target model projects where AbbVie could trade if current growth trends hold.

Year Price Target from 24/7 Wall St. 2026 $274.36 2027 $279.12 2028 $289.22 2029 $300.38 2030 $314.29 These estimates assume AbbVie executes its immunology strategy. Key swing factors: Skyrizi’s patent defense ahead of 2033 expiration and how quickly Apogee drugs reach market.

Contact [email protected] for any questions or corrections.

Pharmaceutical stocks have been one of the best places to invest over the past year. Choosing between these two funds is really a question about how you want to own what comes next.

AbbVie (ABBV +1.49%) has been a favorite for income investors since spinning off from Abbott Labs (ABT +1.13%) in 2013. For much of the past 13 years, the big drugmaker offered one of the more attractive dividend yields in the healthcare sector.

However, AbbVie's dividend yield today hovers around 2.6% -- the lowest level since early 2018. For investors accustomed to collecting yields of 3.5% or more, this relatively smaller amount might not seem appealing. But there's a good case to be made that AbbVie is still a great pick for income investors anyway.

Image source: Getty Images.

What's behind AbbVie's declining dividend yield? There are three ways that a dividend yield can decline. First, a company can cut the dividend while its share price either remains flat or rises. Second, the company's share price can rise while its dividend doesn't change. Third, both the company's share price and dividend can increase, with the share price rising faster than the dividend.

AbbVie is a clear example of the third scenario. The company inherited a long streak of dividend hikes from Abbott and has kept it going. AbbVie is a member of the Dividend Kings, an elite group of stocks with at least 50 consecutive dividend increases. It has grown its dividend (including the period when it was part of Abbott) for 54 consecutive years.

The company's dividend increases haven't been paltry, either. Since 2013, AbbVie's dividend payout has soared by almost 333%. Over the last five years, its dividend has risen 33%.

But AbbVie's share price has grown much more rapidly. The big biotech stock is up roughly 676% since 2013 and has gained 148% over the last five years, handily beating the S&P 500's (^GSPC +0.59%) during the period. Therefore, AbbVie's yield compression is entirely price-driven.

Premium Feature

Moneyball Superscore

79/100

Today's Change

(

1.49

%) $

4.05

Current Price

$

276.47

Blue skies ahead There's more growth ahead for AbbVie. The drugmaker no longer has to worry about the Humira patent cliff. Humira's two successors, Skyrizi and Rinvoq, are on track for combined sales of over $29 billion in 2026. At its peak in 2021, Humira's annual sales were around $22 billion.

Even better, the sales growth for Skyrizi and Rinvoq remains strong. In the second quarter of 2026, sales for both immunology drugs jumped by more than 24% year over year.

AbbVie's lineup also includes other blockbuster growth drivers. Sales for the antipsychotic Vraylar, the migraine therapies Qulipta and Ubrelvy, and the cancer drug Venclexta continue to grow in the double digits.

The company's pipeline features around 90 programs in clinical development, with two-thirds of them in mid- or late-stage testing. That number doesn't include the assets acquired in AbbVie's recent acquisition of Apogee Therapeutics.

Granted, Wall Street doesn't expect huge near-term gains for AbbVie. The consensus 12-month price target reflects only around 5% upside. Some analysts are more optimistic, though. For example, Morgan Stanley's (MS +1.38%) Terence Flynn thinks AbbVie's shares can rise by 14% over the next 12 months, while Scotiabank's (NYSE: BNS) Louise Chen projects a gain of nearly 18%.

AbbVie is still a good pick for income investors for one simple reason: Its dividend is likely to continue growing robustly. A yield of 2.6% isn't all that shabby. However, if AbbVie increases its dividend payouts by its average growth rate over the last five years, investors' yield on cost could easily top 4.6% within the next 10 years.

Don't overlook the peace-of-mind factor, either. AbbVie's dividend yield might not be as high as it once was, but the reliability of the dividends is as strong as ever.

Bell Asset Management Ltd cut its holdings in shares of AbbVie Inc. (NYSE:ABBV – Free Report) by 48.2% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 10,833 shares of the company’s stock after selling 10,062 shares during the quarter. AbbVie makes up approximately 1.0% of Bell Asset Management Ltd’s portfolio, making the stock its 23rd largest holding. Bell Asset Management Ltd’s holdings in AbbVie were worth $2,834,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in ABBV. Burk Holdings LLC bought a new position in AbbVie in the 2nd quarter worth approximately $30,000. Abound Financial LLC purchased a new stake in shares of AbbVie during the fourth quarter worth $32,000. Merkkuri Wealth Advisors LLC bought a new position in shares of AbbVie in the first quarter worth $34,000. Marquette Asset Management LLC grew its position in shares of AbbVie by 52.2% in the second quarter. Marquette Asset Management LLC now owns 140 shares of the company’s stock valued at $35,000 after purchasing an additional 48 shares in the last quarter. Finally, Phillip James Consulting Co. bought a new stake in shares of AbbVie during the 4th quarter valued at $36,000. Institutional investors own 70.23% of the company’s stock.

Insider Activity at AbbVie In related news, EVP Nicholas Donoghoe sold 32,710 shares of the business’s stock in a transaction dated Friday, August 14th. The shares were sold at an average price of $250.00, for a total transaction of $8,177,500.00. Following the transaction, the executive vice president owned 74,430 shares in the company, valued at $18,607,500. The trade was a 30.53% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 0.06% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes ABBV has been the subject of a number of recent analyst reports. Rothschild & Co Redburn lifted their target price on AbbVie from $284.00 to $285.00 and gave the company a “buy” rating in a report on Tuesday, August 4th. HSBC upped their target price on shares of AbbVie from $300.00 to $315.00 and gave the stock a “buy” rating in a report on Thursday, September 10th. Erste Group Bank raised shares of AbbVie from a “hold” rating to a “buy” rating in a report on Wednesday, August 5th. Weiss Ratings upgraded AbbVie from a “hold (c)” rating to a “buy (b-)” rating in a research report on Tuesday, August 4th. Finally, Morgan Stanley lifted their price target on AbbVie from $296.00 to $310.00 and gave the company an “overweight” rating in a research report on Wednesday. One research analyst has rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and six have issued a Hold rating to the company. Based on data from MarketBeat.com, AbbVie currently has a consensus rating of “Moderate Buy” and an average target price of $276.64. Read Our Latest Stock Analysis on AbbVie

AbbVie News Summary Here are the key news stories impacting AbbVie this week:

Positive Sentiment: FDA breakthrough designations for Temab-A: The FDA granted two Breakthrough Therapy Designations to investigational telisotuzumab adizutecan (Temab-A/ABBV-400) for colorectal cancer and non-small cell lung cancer. The designations can accelerate development and regulatory review, while highlighting the potential of AbbVie’s antibody-drug conjugate portfolio. They do not, however, represent an approval or guarantee of commercial success. AbbVie Temab-A FDA Breakthrough Therapy Designations Positive Sentiment: Strong Phase 3 lymphoma data: AbbVie and Genmab reported that epcoritamab plus R-CHOP reduced the risk of disease progression or death by 51% versus R-CHOP alone in newly diagnosed diffuse large B-cell lymphoma. The result supports the potential for broader use of Epkinly/Epkinly and adds another meaningful pipeline catalyst. AbbVie and Genmab Epcoritamab Phase 3 Results Positive Sentiment: Higher analyst price targets: JPMorgan raised its AbbVie target to $300 from $285 and maintained an Overweight rating. Cantor Fitzgerald also raised its target, to $290 from $285, and reiterated Overweight. The revisions indicate analysts see additional upside based on AbbVie’s pipeline and growth outlook. Negative Sentiment: Dividend sustainability concerns: A report highlighted AbbVie’s roughly 190% payout ratio, meaning reported earnings are below the dividend distributed. While noncash charges and other accounting factors can distort this measure, the elevated ratio raises questions about long-term dividend coverage and could weigh on income-focused investors. AbbVie Dividend Payout Concerns AbbVie Price Performance NYSE:ABBV opened at $272.20 on Friday. The company has a market capitalization of $480.92 billion, a price-to-earnings ratio of 76.89, a PEG ratio of 1.23 and a beta of 0.24. The business has a 50 day moving average of $258.56 and a 200 day moving average of $236.35. AbbVie Inc. has a 1-year low of $190.75 and a 1-year high of $274.94.

AbbVie (NYSE:ABBV – Get Free Report) last released its quarterly earnings data on Friday, July 31st. The company reported $3.65 EPS for the quarter, topping the consensus estimate of $3.61 by $0.04. The firm had revenue of $16.99 billion for the quarter, compared to the consensus estimate of $16.80 billion. AbbVie had a negative return on equity of 422.07% and a net margin of 9.80%.The company’s quarterly revenue was up 10.2% on a year-over-year basis. During the same quarter in the previous year, the business earned $2.97 earnings per share. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. As a group, sell-side analysts anticipate that AbbVie Inc. will post 14.01 EPS for the current year.

AbbVie Dividend Announcement The firm also recently announced a quarterly dividend, which will be paid on Monday, November 16th. Investors of record on Thursday, October 15th will be issued a dividend of $1.73 per share. This represents a $6.92 dividend on an annualized basis and a dividend yield of 2.5%. The ex-dividend date is Thursday, October 15th. AbbVie’s dividend payout ratio is currently 195.48%.

AbbVie Company Profile (Free Report)

AbbVie Inc is a global biopharmaceutical company that develops, manufactures and markets medicines for a range of serious and chronic health conditions. Its portfolio spans immunology, oncology, neuroscience, eye care, aesthetics, gastroenterology and women’s health.

The company’s products include the immunology medicines Skyrizi and Rinvoq; neuroscience treatments such as Vraylar, Ubrelvy and Qulipta; and oncology medicines including Imbruvica and Venclexta. AbbVie also markets Botox Cosmetic and Botox Therapeutic, as well as other products for aesthetics, eye care and specialty care.

AbbVie was established in 2013 as an independent, publicly traded company following its separation from Abbott Laboratories.

See Also Five stocks we like better than AbbVie Want Private-Market Access to Kalshi and Polymarket? Try This ETF Levi’s Stock Dip Reveals Value Opportunity Despite Q3 Headwinds PepsiCo Stock Looks Poised to Bottom With High Yield, Deep Value Alphabet’s $1.8 Billion Black Hills Deal Powers AI Data Center Push Want to see what other hedge funds are holding ABBV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AbbVie Inc. (NYSE:ABBV – Free Report).

Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with MarketBeat.com's FREE daily email newsletter.